Alzheimer’s disease (AD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS) are the most common human adult-onset neurodegenerative diseases. They are characterized by prominent age-related neurodegeneration in selectively vulnerable neural systems. Some forms of AD, PD, and ALS are inherited, and genes causing these diseases have been identified. Nevertheless, the mechanisms of the neuronal cell death are unresolved. Morphological, biochemical, genetic, as well as cell and animal model studies reveal that mitochondria could have roles in this neurodegeneration. The functions and properties of mitochondria might render subsets of selectively vulnerable neurons intrinsically susceptible to cellular aging and stress and overlying genetic variations, triggering neurodegeneration according to a cell death matrix theory. In AD, alterations in enzymes involved in oxidative phosphorylation, oxidative damage, and mitochondrial binding of Aβ and amyloid precursor protein have been reported. In PD, mutations in putative mitochondrial proteins have been identified and mitochondrial DNA mutations have been found in neurons in the substantia nigra. In ALS, changes occur in mitochondrial respiratory chain enzymes and mitochondrial cell death proteins. Transgenic mouse models of human neurodegenerative disease are beginning to reveal possible principles governing the biology of selective neuronal vulnerability that implicate mitochondria and the mitochondrial permeability transition pore. This review summarizes how mitochondrial pathobiology might contribute to neuronal death in AD, PD, and ALS and could serve as a target for drug therapy.
References
[1]
Virchow, R. Cellular Pathology as Based Upon Physiological and Pathological Histology; John Churchill: London (Translation), UK, 1860.
[2]
Martin, L.J. Neurodegenerative disorders of the human brain and spinal cord. In Encyclopedia of the Human Brain; Ramachandran, V.S., Ed.; Elsevier Science Academic Press: San Diego, USA, 2002; Volume 3, pp. 441–463.
[3]
Rich, T.; Allen, R.L.; Wyllie, A.H. Defying death after DNA damage. Nature？2000, 407, 777–783, doi:10.1038/35037717. 11048728
[4]
Zheng, T.S. Death by design: the big debut of small molecules. Nat. Cell Biol.？2001, 3, E1–E3, doi:10.1038/35050631. 11146635
[5]
Martin, L.J. Mitochondriopathy in Parkinson’s disease and amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol.？2006, 65, 1103–1110, doi:10.1097/01.jnen.0000248541.05552.c4. 17146283
Nicholls, D.G. Mitochondrial function and dysfunction in the cell: its relevance to aging and aging-related disease. Intl. J. Biochem. Cell Biol.？2002, 34, 1372–1381, doi:10.1016/S1357-2725(02)00077-8.
[8]
Wallace, D.C. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn of evolutionary medicine. Annu. Rev. Genet.？2005, 39, 359–407, doi:10.1146/annurev.genet.39.110304.095751. 16285865
[9]
Fridovich, I. Superoxide radical and superoxide dismutases. Annu. Rev. Biochem.？1995, 64, 97–112, doi:10.1146/annurev.bi.64.070195.000525. 7574505
[10]
Halliwell, B. Role of free radicals in the neurodegenerative diseases. Drugs Aging？2001, 18, 685–716, doi:10.2165/00002512-200118090-00004. 11599635
[11]
Mungrue, I.N.; Bredt, D.S.; Stewart, D.J.; Husain, M. From molecules to mammals: what’s NOS got to do with it? Acta Physiol. Scand.？2003, 179, 123–135, doi:10.1046/j.1365-201X.2003.01182.x. 14510775
[12]
Beckman, J.S.; Carson, M.; Smith, C.D.; Koppenol, W.H. ALS, SOD and peroxynitrite. Nature？1993, 364, 548, doi:10.1038/364548a0. 8393148
[13]
Martin, L.J.; Liu, Z. DNA damage profiling in motor neurons: a single-cell analysis by comet assay. Neurochem. Res.？2002, 27, 1089–1100.
[14]
Giulini, C. Characterization and function of mitochondrial nitric-oxide synthase. Free Radic. Biol. Med.？2003, 34, 397–408, doi:10.1016/S0891-5849(02)01298-4. 12566065
[15]
Brown, G.C.; Borutaite, V. Nitric oxide, cytochrome c, and mitochondria. Biochem. Soc. Sym.？1999, 66, 17–25.
Martin, L.J.; Al-Abdulla, N.A.; Brambrink, A.M.; Kirsch, J.R.; Sieber, F.E.; Portera-Cailliau, C. Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: a perspective on the contributions of apoptosis and necrosis. Brain Res. Bull.？1998, 46, 281–309, doi:10.1016/S0361-9230(98)00024-0. 9671259
[18]
Northington, F.J.; Graham, E.M.; Martin, L.J. Apoptosis in perinatal hypoxic-ischemic brain injury: how important is it and should it be inhibited? Brain Res. Rev.？2005, 50, 244–257, doi:10.1016/j.brainresrev.2005.07.003.
[19]
Martin, L.J. The mitochondrial permeability transition pore: a molecular target for amyotrophic lateral sclerosis. Biochim. Biophys. Acta？2010, 1802, 186–197. 19651206
[20]
Waldmeier, P.C.; Zimmermann, K.; Qian, T.; Tintelnot-Blomley, M.; Lemasters, J.J. Cyclophilin D as a drug target. Curr. Med. Chem.？2003, 10, 1485–1506, doi:10.2174/0929867033457160. 12871122
[21]
Crompton, M. Mitochondria and aging: a role for the permeability transition? Aging Cell？2004, 3, 3–6, doi:10.1046/j.1474-9728.2003.00073.x. 14965348
[22]
Halestrap, A.P. What is the mitochondrial permeability transition pore? J. Mol. Cell Cardiol.？2009, 46, 821–831, doi:10.1016/j.yjmcc.2009.02.021. 19265700
[23]
Bernardi, P.; Krauskopf, A; Basso, E.; Petronilli, V.; Blalchy-Dyson, E.; Di Lisa, F.; Forte, M.A. The mitochondrial permeability transition from in vitro artifact to disease target. FEBS J.？2006, 273, 2077–2099. 16649987
[24]
Martin, L.J. Neuronal cell death in nervous system development, disease, and injury. Int. J. Mol. Med.？2001, 7, 455–478. 11295106
Gilbert, S. Developmental Biology; Sinauer Associates: Sunderland, MA, USA, 2006.
[27]
Klionsky, D.J.; Emr, S.D. Autophagy as a regulated pathway of cellular degradation. Science？2000, 290, 1717–1721, doi:10.1126/science.290.5497.1717. 11099404
[28]
Portera-Cailliau, C.; Price, D.L.; Martin, L.J. Excitotoxic neuronal death in the immature brain is an apoptosis-necrosis morphological continuum. J. Comp. Neurol.？1997, 378, 70–87. 9120055
[29]
Portera-Cailliau, C.; Price, D.L.; Martin, L.J. Non-NMDA and NMDA receptor-mediated excitotoxic neuronal deaths in adult brain are morphologically distinct: further evidence for an apoptosis-necrosis continuum. J. Comp. Neurol.？1997, 378, 88–104, doi:10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G. 9120056
[30]
Formigli, L.; Papucci, L.; Tani, N.; Schiavone, N.; Tempestini, A.; Orlandini, G.E.; Capaccioli, S.; Zecchi Orlandini, S. Aponecrosis: morphological and biochemical exploration of a syncretic process of cell death sharing apoptosis and necrosis. J Cell. Physiol.？2000, 182, 41–49, doi:10.1002/(SICI)1097-4652(200001)182:1<41::AID-JCP5>3.0.CO;2-7. 10567915
[31]
Lennon, S.V.; Martin, S.J.; Cotter, T.G. Dose-dependent induction of apoptosis in human tumour cell lines by widely diverging stimuli. Cell Prolif.？1991, 24, 203–214, doi:10.1111/j.1365-2184.1991.tb01150.x. 2009322
[32]
Fernandes, R.S.; Cotter, T.G. Apoptosis or necrosis: intracellular levels of glutathione influence mode of cell death. Biochem. Pharmacol.？1994, 48, 675–681, doi:10.1016/0006-2952(94)90044-2. 8080440
[33]
Bonfoco, E.; Krainc, D.; Ankarcrona, M.; Nicotera, P.; Lipton, S.A. Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell culture. Proc. Natl. Acad. Sci. USA？1995, 92, 7162–7166, doi:10.1073/pnas.92.16.7162. 7638161
[34]
Raffray, M.; Cohen, G.M. Apoptosis and necrosis in toxicology: a continuum or distinct modes of cell death? Pharmacol. Ther.？1997, 75, 153–177, doi:10.1016/S0163-7258(97)00037-5. 9504137
[35]
Yuan, J.; Lipinski, M.; Degterev, A. Diversity in the mechanisms of neuronal cell death. Neuron？2003, 40, 401–413, doi:10.1016/S0896-6273(03)00601-9. 14556717
[36]
Orrenius, S.; Zhivotovsky, B.; Nicotera, P. Regulation of cell death: the calcium-apoptosis link. Nat. Rev.？2003, 4, 552–565, doi:10.1038/nrm1150.
[37]
Youle, R.J.; Strasser, A. The Bcl-2 protein family: opposing activities that mediate cell death. Nat. Rev.？2008, 9, 47–59, doi:10.1038/nrm2308.
[38]
Merry, D.E.; Korsmeyer, S.J. Bcl-2 gene family in the nervous system. Ann. Rev. Neurosci.？1997, 20, 245–267, doi:10.1146/annurev.neuro.20.1.245. 9056714
[39]
Trump, B.F.; Berezesky, I.K. The role of altered [Ca2+]i regulation in apoptosis, oncosis, and necrosis. Biochim. Biophys. Acta？1996, 1313, 173–178, doi:10.1016/0167-4889(96)00086-9.
[40]
Majno, G.; Joris, I. Apoptosis, oncosis, and necrosis. An overview of cell death. Am. J. Pathol.？1995, 146, 3–15. 7856735
[41]
Trump, B.J.; Goldblatt, P.J.; Stowell, R.E. Studies on necrosis of mouse liver in vitro. Ultrastructural alterations in the mitochondria of hepatic parenchymal cells. Lab. Invest.？1964, 14, 343–371.
[42]
Leist, M.; Single, B.; Castoldi, A.F.; Kuhnles, S.; Nicotera, P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J. Exp. Med.？1997, 185, 1481–1486, doi:10.1084/jem.185.8.1481. 9126928
[43]
Martin, L.J.; Brambrink, A.M.; Price, A.C.; Kaiser, A.; Agnew, D.M.; Ichord, R.N.; Traystman, R.J. Neuronal death in newborn striatum after hypoxia-ischemia is necrosis and evolves with oxidative stress. Neurobiol. Dis.？2000, 7, 169–191, doi:10.1006/nbdi.2000.0282. 10860783
[44]
Golden, W.C.; Brambrink, A.M.; Traystman, R.J.; Martin, L.J. Failure to sustain recovery of Na,K ATPase function is a possible mechanism for striatal neurodegeneration in hypoxic-ischemic newborn piglets. Mol. Brain Res.？2001, 88, 94–102, doi:10.1016/S0169-328X(01)00032-8.
[45]
Castro, J.; Ruminot, I.; Porras, O.H.; Flores, C.M.; Hermosilla, T.; Verdugo, E.; Venegas, F.; Hartel, S.; Michea, L.; Barros, L.F. ATP steal between cation pumps: a mechanism linking Na+ influx to the onset or necrotic Ca2+ overload. Cell Death Diff.？2006, 13, 1675–1685, doi:10.1038/sj.cdd.4401852.
[46]
Proskuryakov, S.Y.; Konoplyannikov, A.G.; Gabai, V.L. Necrosis: a specific form of programmed cell death. Exp. Cell Res.？2003, 283, 1–16, doi:10.1016/S0014-4827(02)00027-7. 12565815
[47]
Kim, Y-S.; Morgan, M.J.; Choksi, S.; Lu, Z-G. TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. Mol. Cell？2007, 26, 675–687, doi:10.1016/j.molcel.2007.04.021. 17560373
[48]
Hitomi, J.; Christofferson, D.E.; Ng, A.; Yao, J.; Degterev, A.; Xavier, R.J.; Yuan, J. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell？2008, 135, 1311–1323, doi:10.1016/j.cell.2008.10.044. 19109899
[49]
Ha, H.C.; Snyder, S.H. Poly(ADP-ribose) polymerase-1 in the nervous system. Neurobiol. Dis.？2000, 7, 225–239, doi:10.1006/nbdi.2000.0324. 10964595
[50]
Zoratti, M.; Szabo, I. The mitochondrial permeability transition. Biochem. Biophys. Acta？1995, 1241, 139–176. 7640294
[51]
Crompton, M. The mitochondrial permeability transition pore and its role in cell death. Biochem. J.？1999, 341, 233–249, doi:10.1042/0264-6021:3410233. 10393078
[52]
Van Gurp, M.; Festjens, N.; van Loo, G.; Saelens, X.; Vandenabeele, P. Mitochondrial intermembrane proteins in cell death. Biochem. Biophys. Res. Comm.？2003, 304, 487–497, doi:10.1016/S0006-291X(03)00621-1. 12729583
[53]
Leung, A.W.C.; Halestrap, A.P. Recent progress in elucidating the molecular mechanism of the mitochondrial permeability transition pore. Biochim. Biophys. Acta？2008, 1777, 946–952, doi:10.1016/j.bbabio.2008.03.009. 18407825
[54]
Shoshan-Barmatz, V.; Israelson, A.; Brdiczka, D.; Sheu, S.S. The voltage-dependent anion channel (VDAC): function in intracellular signaling, cell life and cell death. Curr. Pharm. Des.？2006, 12, 2249–2270, doi:10.2174/138161206777585111. 16787253
[55]
Rostovtseva, T.K.; Tan, W.; Colombini, M. On the role of VDAC in apoptosis: fact and fiction. J. Bioenerget. Biomembr.？2005, 37, 129–142, doi:10.1007/s10863-005-6566-8.
[56]
Granville, D.J.; Gottlieb, R.A. The mitochondrial voltage-dependent anion channel (VDAC) as a therapeutic target for initiating cell death. Curr. Med. Chem.？2003, 10, 1527–1533, doi:10.2174/0929867033457214. 12871124
[57]
Huizing, M.; Ruitenbeek, W.; van den Heuvel, L.P.; Dolce, V.; Iacobazzi, V.; Smeitink, J.A.M.; Palmieri, F.; Trijbels, J.M.F. Human mitochondrial transmembrane metabolite carriers: tissue distribution and its implication for mitochondrial disorders. J. Bioenerg. Biomembr.？1998, 30, 277–284, doi:10.1023/A:1020501021222. 9733094
[58]
Wu, S.; Sampson, M.J.; Decker, W.K.; Craigen, W.J. Each mammalian mitochondrial outer membrane porin protein is dispensable: effects on cellular respiration. Biochem. Biophys. Acta？1999, 1452, 68–78, doi:10.1016/S0167-4889(99)00120-2.
[59]
Anflous, K.; Armstrong, D.D.; Craigen, W.J. Altered sensitivity for ADP and maintenance of creatine-stimulated respiration in oxidative striated muscles from VDAC1-deficient mice. J. Biol. Chem.？2001, 276, 1954–1960. 11044447
[60]
Sampson, M.J.; Decker, W.K.; Beaudet, A.L.; Ruitenbeek, W.; Armstrong, D.; Hicks, M.J.; Craigen, W.J. Immotile sperm and infertility in mice lacking mitochondrial voltage-dependent anion channel type 3. J. Biol. Chem.？2001, 276, 39206–39212, doi:10.1074/jbc.M104724200. 11507092
Karachitos, A.; Galganska, H.; Wojtkowska, M.; Budzinska, M.; Stobienia, O.; Bartosz, G.; Kimita, H. Cu,Zn-superoxide dismutase is necessary for proper function of VDAC in Saccharomyces cerevisiae cells. FEBS Lett.？2009, 583, 449–455, doi:10.1016/j.febslet.2008.12.045. 19116152
[65]
Halestrap, A.P.; Brenner, C. The adenine nucleotide translocase: a central component of the mitochondrial permeability transition pore and key player in cell death. Curr. Med. Chem.？2003, 10, 1507–1525, doi:10.2174/0929867033457278. 12871123
[66]
Graham, B.H.; Waymire, K.G.; Cottrell, B.; Trounce, I.A.; MacGregor, G.R.; Wallace, D.C. A mouse model for mitochondrial myopathy and cardiomyopathy resulting from a deficiency in the heart/muscle isoform of the adenine nucleotide translocator. Nat. Genet.？1997, 16, 226–234, doi:10.1038/ng0797-226. 9207786
[67]
Stepien, G.; Torroni, A.; Chung, A.B.; Hodge, J.A.; Wallace, D.C. Differential expression of adenine nucleotide translocator isoforms in mammalian tissues and during muscle cell differentiation. J. Bio. Chem.？1992, 267, 14592–14597.
[68]
Vyssokikh, M.Y.; Katz, A.; Rueck, A.; Wuensch, C.; Dorner, A.; Zorov, D.B.; Brdiczka, D. Adenine nucleotide translocator isoforms 1 and 2 are differently distributed in the mitochondrial inner membrane and have distinct affinities to cyclophilin D. Biochem. J.？2001, 358, 349–358, doi:10.1042/0264-6021:3580349. 11513733
[69]
Kikoszka, J.E.; Waymire, K.G.; Levy, S.E.; Sligh, J.E.; Cai, J.; Jones, D.P.; MacGregor, G.R.; Wallace, D.C. The ADP/ATP translocator is not essential for the mitochondrial permeability transition pore. Nature？2004, 427, 461–465. 14749836
[70]
Machida, K.; Hayashi, Y.; Osada, H. A novel adenine nucleotide translocase inhibitor, MT-21, induces cytochrome c release through a mitochondrial permeability transition-independent mechanisms. J. Biol. Chem.？2002, 277, 31243–31248. 12063261
[71]
Baines, C.P.; Kaiser, R.A.; Purcell, N.H.; Blair, H.S.; Osinska, H.; Hambleton, M.A.; Brunskill, E.W.; Sayen, M.R.; Gottlieb, R.A.; Dorn II, G.W.; Robbins, J.; Molkentin, J.D. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature？2005, 434, 658–662, doi:10.1038/nature03434. 15800627
[72]
Woodfield, K.; Rück, A.; Brdiczka, D.; Halestrap, A.P. Direct demonstration of a specific interaction between cyclophilin-D and the adenine nucleotide translocase confirms their role in the mitochondrial permeability transition. Biochem. J.？1998, 336, 287–290. 9820802
[73]
Johnson, N.; Khan, A.; Virji, S.; Ward, J.M.; Crompton, M. Import and processing of heart mitochondrial cyclophilin D. Eur. J. Biochem.？1999, 263, 353–359, doi:10.1046/j.1432-1327.1999.00490.x. 10406942
Shoshan-Barmatz, V.; Zalk, R.; Gincel, D.; Vardi, N. Subcellular localization of VDAC in mitochondria and ER in the cerebellum. Biochem. Biophys. Acta？2004, 1657, 105–114, doi:10.1016/j.bbabio.2004.02.009.
[76]
Akanda, N.; Tofight, R.; Brask, J.; Tamm, C.; Elinder, F.; Ceccatelli, S. Voltage-dependent anion channels (VDAC) in the plasma membrane play a critical role in apoptosis in differentiated hippocampal neurons but not in neural stem cells. Cell Cycle？2008, 7, 3225–3234, doi:10.4161/cc.7.20.6831. 18927501
[77]
Yu, W.H.; Wolfgang, W.; Forte, M. Subcellular localization of human voltage-dependent anion channel isoforms. J. Biol. Chem.？1995, 270, 13998–14006, doi:10.1074/jbc.270.23.13998. 7539795
Hazelton, J.L.; Petrasheuskaya, M.; Fiskum, G.; Kristian, T. Cyclophilin D is expressed predominantly in mitochondria of γ-aminobutyric acidergic interneurons. J. Neurosci. Res.？2009, 87, 1250–1259, doi:10.1002/jnr.21921. 18951528
[80]
Naga, K.K.; Sullivan, P.G.; Geddes, J.W. High cyclophilin D content of synaptic mitochondria results in increased vulnerability to permeability transition. J. Neurosci.？2007, 27, 7469–7475, doi:10.1523/JNEUROSCI.0646-07.2007. 17626207
[81]
Martin, L.J.; Gertz, B.; Pan, Y.; Price, A.C.; Molkentin, J.D.; Chang, Q. The mitochondrial permeability transition pore in motor neurons: involvement in the pathobiology of ALS mice. Exp. Neurol.？2009, 218, 333–346, doi:10.1016/j.expneurol.2009.03.034. 19348801
[82]
Bose, S.; Freedman, R.B. Peptidyl prolyl cis-trans-isomerase activity associated with the lumen of the endoplasmic reticulum. Biochem. J.？1994, 300, 865–870. 8010971
[83]
Sullivan, P.G.; Rabchevsky, A.G.; Keller, J.N.; Lovell, M.; Sodhi, A.; Hart, R.P.; Scheff, S.W. Intrinsic differences in brain and spinal cord mitochondria: implications for therapeutic interventions. J. Comp. Neurol.？2004, 474, 524–534, doi:10.1002/cne.20130. 15174070
[84]
Morota, S.; Hansson, M.J.; Ishii, N.; Kudo, Y.; Elmer, E.; Uchino, H. Spinal cord mitochondria display lower calcium retention capacity compared with brain mitochondria without inherent differences in sensitivity to cyclophilin D inhibition. J. Neurochem.？2007, 103, 2066–2076, doi:10.1111/j.1471-4159.2007.04912.x. 17868326
[85]
Collins, T.J.; Bootman, M.D. Mitochondria are morphologically heterogeneous within cells. J. Exp. Biol.？2003, 206, 1993–2000, doi:10.1242/jeb.00244. 12756281
[86]
Jensen, R.E. Control of mitochondrial shape. Curr. Opin. Cell Biol.？2005, 17, 384–388, doi:10.1016/j.ceb.2005.06.011. 15975781
[87]
Hamberger, A.; Blomstrand, C.; Lehninger, A.L. Comparative studies of mitochondria isolated from neuron-enriched and glia-enriched fractions of rabbit and beef brain. J. Cell Biol.？1970, 45, 221–234, doi:10.1083/jcb.45.2.221. 5513605
[88]
Tata, J.R. Requirement for RNA and protein synthesis for induced regression of tadpole tail in organ culture. Dev. Biol.？1966, 13, 77–94, doi:10.1016/0012-1606(66)90050-9. 5923195
[89]
Chipuk, J.E.; Green, D.R. p53’s believe it or not: lessons on transcription-independent death. J. Clin. Immunol.？2003, 23, 355–361, doi:10.1023/A:1025365432325. 14601643
[90]
Martin, L.J.; Liu, Z.; Pipino, J.; Chestnut, B.; Landek, M.A. Molecular regulation of DNA damage-induced apoptosis in neurons of cerebral cortex. Cereb. Cortex？2009, 19, 1273–1293, doi:10.1093/cercor/bhn167. 18820287
[91]
Kerr, J.F.R.; Wyllie, A.H.; Currie, A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer？1972, 26, 239–257, doi:10.1038/bjc.1972.33. 4561027
[92]
Schwartz, L.M.; Smith, S.W.; Jones, M.E.; Osborne, B.A. Do all programmed cell deaths occur via apoptosis? Proc. Natl. Acad. Sci. USA？1993, 90, 980–984, doi:10.1073/pnas.90.3.980. 8430112
[93]
Amin, F.; Bowen, I.D.; Szegedi, Z.; Mihalik, R.; Szende, B. Apoptotic and non-apoptotic modes of programmed cell death in MCF-7 human breast carcinoma cells. Cell Biol. Intl.？2000, 24, 253–260, doi:10.1006/cbir.2000.0495.
[94]
Jacobson, M. Developmental Neurobiology; Plenum Press: New York, NY, USA, 1991.
[95]
Glücksmann, A. Cell deaths in normal vertebrate ontogeny. Biol. Rev.？1951, 26, 59–86, doi:10.1111/j.1469-185X.1951.tb00774.x. 24540363
[96]
Lockshin, R.A.; Williams, C.M. Programmed cell death: II. Endocrine potentiation of the breakdown of the intersegmental muscles of silkmoths. J. Insect Physiol.？1964, 10, 643–649, doi:10.1016/0022-1910(64)90034-4.
[97]
Saunders, J.W. Death in embryonic systems. Science？1966, 154, 604–612, doi:10.1126/science.154.3749.604. 5332319
[98]
Bursch, W.; Paffe, S.; Putz, B.; Barthel, G.; Schulte-Hermann, R. Determination of the length of the histological stages of apoptosis in normal liver and in altered hepatic foci of rats. Carcinogenesis？1990, 11, 847–853, doi:10.1093/carcin/11.5.847. 2139818
[99]
Wyllie, A.H.; Kerr, J.F.R.; Currie, A.R. Cell death: the significance of apoptosis. Int. Rev. Cytol.？1980, 68, 251–306. 7014501
Wyllie, A.H. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature？1980, 284, 555–556, doi:10.1038/284555a0. 6245367
[103]
Liu, X.; Zou, H.; Slaughter, C.; Wang, X. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis. Cell？1997, 89, 175–184, doi:10.1016/S0092-8674(00)80197-X. 9108473
[104]
Sakahira, H.; Enari, M.; Ohsawa, Y.; Uchiyama, Y.; Nagata, S. Apoptotic nuclear morphological change without DNA fragmentation. Curr. Biol.？1999, 9, 543–546, doi:10.1016/S0960-9822(99)80240-1. 10339431
[105]
Pilar, G.; Landmesser, L. Ultrastructural differences during embryonic cell death in normal and peripherally deprived ciliary ganglia. J. Cell Biol.？1976, 68, 339–356, doi:10.1083/jcb.68.2.339. 942724
[106]
Nakajima, W.; Ishida, A.; Lange, M.S.; Gabrielson, K.L.; Wilson, M.A.; Martin, L.J.; Blue, M.E.; Johnston, M.V. Apoptosis has a prolonged role in the neurodegeneration after hypoxic ischemia in the newborn rat. J. Neurosci.？2000, 20, 7994–8004. 11050120
[107]
Northington, F.J.; Ferriero, D.M.; Graham, E.M.; Traystman, R.J.; Martin, L.J. Early neurodegeneration after hypoxia-ischemia in neonatal rat is necrosis while delayed neuronal death is apoptosis. Neurobiol. Dis.？2001, 8, 207–219, doi:10.1006/nbdi.2000.0371. 11300718
[108]
Northington, F.J.; Zelaya, M.E.; O’Riordan, D.P.; Blomgren, K.; Flock, D.L.; Hagberg, H.; Ferriero, D.M.; Martin, L.J. Failure to complete apoptosis following neonatal hypoxia-ischemia manifests as “continuum” phenotype of cell death and occurs with multiple manifestations of mitochondrial dysfunction in rodent forebrain. Neuroscience？2007, 149, 822–833, doi:10.1016/j.neuroscience.2007.06.060. 17961929
[109]
Schweichel, J.U.; Merker, H.J. The morphology of various types of cell death in prenatal tissues. Teratology？1973, 7, 253–266, doi:10.1002/tera.1420070306. 4807128
[110]
Xue, L. Z.; Fletcher, G. C.; Tolkovsky, A. M. Autophagy is activated by apoptotic signaling in sympathetic neurons: an alternative mechanism of death execution. Mol. Cell. Neurosci.？1999, 14, 180–198, doi:10.1006/mcne.1999.0780. 10576889
[111]
Yue, Z.; Horton, A.; Bravin, M.; DeJager, P.L.; Selimi, F.; Heintz, N. A novel protein complex linking the δ2 glutamate receptor and autophagy: implications for neurodegeneration in Lurcher mice. Neuron？2002, 35, 921–933. 12372286
[112]
Hara, T.; Nakamura, K.; Matsui, M.; Yamamoto, A.; Nakahara, Y.; Suzuki-Migishima, R.; Yokoyama, M.; Mishima, K.; Saito, I.; Okano, H.; Misushima, N. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature？2006, 44, 885–889.
[113]
Komatsu, M.; Waguri, S.; Chiba, T.; Murata, S.; Iwata, J.; Tanida, I.; Ueno, T.; Koike, M.; Uchiyama, Y.; Kominami, E.; Tanaka, K. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature？2006, 44, 880–884.
[114]
Nakendra, D.; Tanaka, A.; Suen, D-F.; Youle, R.J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol.？2008, 183, 795–803, doi:10.1083/jcb.200809125. 19029340
[115]
Todde, V.; Veenhuis, M.; van der Klei, I.J. Autophagy: principles and significance in health and disease. Biochim. Biophys. Acta？2009, 1792, 3–13. 19022377
[116]
Bursch, W. The autophagosomal-lysosomal compartment in programmed cell death. Cell Death Diff.？2001, 8, 569–581, doi:10.1038/sj.cdd.4400852.
[117]
Inbal, B.; Bialik, S.; Sabanay, I.; Shani, G.; Kimchi, A. DAP kinase and DRP-1 mediate membrane blebbing and the formation of autophagic vesicles during programmed cell death. J. Cell Biol.？2002, 157, 455–468, doi:10.1083/jcb.200109094. 11980920
[118]
Liange, X.H.; Kleeman, L.K.; Jiang, H.H.; Gordon, G.; Goldman, J.E.; Berry, G.; Herman, B.; Levine, B. Protection against fatal Sindbis virus encephalitis by beclin, a novel Bcl-2-interacting protein. J. Virol.？1998, 72, 8586–8596. 9765397
[119]
Ogier-Denis, E.; Codogno, P. Autophagy: a barrier or an adaptive response to cancer. Biochim. Biophys. Acta？2003, 1603, 113–128. 12618311
[120]
Ameisen, J.C. On the origin, evolution, and nature of programmed cell death: a timeline of four billion years. Cell Death Diff.？2002, 9, 367–393, doi:10.1038/sj.cdd.4400950.
[121]
Metzstein, M.M.; Stanfield, G.M.; Horvitz, H.R. Genetics of programmed cell death in C. elegans: past, present and future. Trends Genet.？1998, 14, 410–416, doi:10.1016/S0168-9525(98)01573-X. 9820030
[122]
Cory, S.; Adams, J.M. The bcl-2 family: regulators of the cellular life-or-death switch. Nat. Rev.？2002, 2, 647–656, doi:10.1038/nrc883.
[123]
Wolf, B.B.; Green, D.R. Suicidal tendencies: apoptotic cell death by caspase family proteinases. J. Biol. Chem.？1999, 274, 20049–20052, doi:10.1074/jbc.274.29.20049. 10400609
[124]
Levrero, M.; De Laurenzi, V.; Costanzo, A.; Sabatini, S.; Gong, J.; Wang, J.Y.J.; Melino, G. The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J. Cell Sci.？2000, 113, 1661–1670. 10769197
[125]
Li, P.; Nijhawan, D.; Budihardjo, I.; Srinivasula, S.M.; Ahmad, M.; Alnemri, E.S.; Wang, X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell？1997, 91, 479–489, doi:10.1016/S0092-8674(00)80434-1. 9390557
[126]
Liu, X.; Kim, C.N.; Yang, J.; Jemmerson, R.; Wang, X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell？1996, 86, 147–157, doi:10.1016/S0092-8674(00)80085-9. 8689682
Hegde, R.; Srinivasula, S.M.; Zhang, Z.; Wassell, R.; Mukattash, R.; Cilentei, L.; DuBois, G.; Lazebnik, Y.; Zervos, A.S.; Fernandes-Alnemri, T.; Alnemri, E.S. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J. Biol. Chem.？2002, 277, 4432–4538.
[129]
Liston, P.; Roy, N.; Tamai, K.; Lefebvre, C.; Baird, S.; Cherton-Horvat, G.; Farahani, R.; McLean, M.; Ikeda, J-E.; MacKenzie, A.; Korneluk, R.G. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature？1996, 379, 349–353. 8552191
[130]
Scorrano, L.; Oakes, S.A.; Opferman, T.J.; Cheng, E.H.; Sorcinelli, M.D.; Pozzan, T.; Korsmeyer, S.J. Bax and Bak regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science？2003, 300, 135–139, doi:10.1126/science.1081208. 12624178
[131]
Muchmore, S.W.; Sattler, M.; Liang, H.; Meadows, R.P.; Harlan, J.E.; Yoon, H.S.; Nettesheim, D.; Chang, B.S.; Thompson, C.B.; Wong, S.L.; Fesik, S.W. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature？1999, 381, 335–341.
[132]
Martin, L.J.; Price, A.C.; McClendon, K.B.; Al-Abdulla, N.A.; Subramaniam, J.R.; Wong, P.C.; Liu, Z. Early events of target deprivation/axotomy-induced neuronal apoptosis in vivo: oxidative stress, DNA damage, p53 phosphorylation and subcellular redistribution of death proteins. J. Neurochem.？2003, 85, 234–247, doi:10.1046/j.1471-4159.2003.01659.x. 12641745
[133]
Wolter, K.G.; Hsu, Y-T.; Smith, C.L.; Nechushtan, A.; Xi, X-G.; Youle, R.L. Movement of Bax from the cytosol to mitochondria during apoptosis. J. Cell Biol.？1997, 139, 1281–1292. 9382873
[134]
Nechushtan, A.; Smith, C.L.; Lamensdorf, I.; Yoon, S-H.; Youle, R.J. Bax and Bak coalesce into novel mitochondria-associated clusters during apoptosis. J. Cell Biol.？2001, 153, 1265–1276. 11402069
Shimizu, S.; Ide, T.; Yanagida, T.; Tsujimoto, Y. Electrophysiological study of a novel large pore formed by Bax and the voltage-dependent anion channel that is permeable to cytochrome c. J. Biol. Chem.？2000, 275, 12321–12325, doi:10.1074/jbc.275.16.12321. 10766872
[137]
Kluck, R.M.; Bossy-Wetzel, E.; Green, D.R.; Newmeyer, D.D. The release of cytochrome c from mitochondria: a primary site for bcl-2 regulation of apoptosis. Science？1997, 275, 1132–1136, doi:10.1126/science.275.5303.1132. 9027315
[138]
Yang, J.; Liu, X.; Bhalla, K.; Kim, C.N.; Ibrado, A.M.; Cai, J.; Peng, T-I.; Jones, D.P.; Wang, X. Prevention of apoptosis by bcl-2: release of cytochrome c from mitochondria blocked. Science？1997, 275, 1129–1132, doi:10.1126/science.275.5303.1129. 9027314
[139]
Vander Heiden, M.G.; Chandel, N.S.; Williamson, E.K.; Schumacker, P.T.; Thompson, C.B. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell？1997, 91, 627–637, doi:10.1016/S0092-8674(00)80450-X. 9393856
[140]
Letai, A.; Bassik, M.C.; Walensky, L.D.; Sorcinelli, M.D.; Weiler, S.; Korsmeyer, S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell？2002, 2, 183–192, doi:10.1016/S1535-6108(02)00127-7. 12242151
[141]
Wei, M.C.; Zong, W-X.; Cheng, E.H.-Y.; Lindsten, T.; Panoutsakopoulou, V.; Ross, A.J.; Roth, K.A.; MacGregor, G.R.; Thompson, C.B.; Korsmeyer, S.J. Proapoptotic Bax and Bak: a requisite gateway to mitochondrial dysfunction and death. Science？2001, 292, 727–730. 11326099
[142]
Hu, Y.; Benedict, M.A.; Wu, D.; Inohara, N.; Nú？ez, G. Bcl-xL interacts with Apaf-1 and inhibits Apaf-1-dependent caspase-9 activation. Proc. Natl. Acad. Sci. USA？1998, 95, 4386–4391, doi:10.1073/pnas.95.8.4386. 9539746
[143]
Song, Q.; Kuang, Y.; Dixit, V.M.; Vincenz, C. Boo, a negative regulator of cell death, interacts with Apaf-1. EMBO J.？1999, 18, 167–178, doi:10.1093/emboj/18.1.167. 9878060
[144]
Haldar, S.; Jena, N.; Croce, C.M. Inactivation of Bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA？1995, 92, 4507–4511, doi:10.1073/pnas.92.10.4507. 7753834
[145]
Wang, H-G.; Rapp, U.R.; Reed, J.C. Bcl-2 targets the protein kinase raf-1 to mitochondria. Cell？1996, 87, 629–638. 8929532
[146]
Datta, S.R.; Dudek, H.; Tao, X.; Masters, S.; Fu, H.; Gotoh, Y.; Greenberg, M.E. Akt phosphorylation of Bad couples survival signals to the cell-intrinsic death machinery. Cell？1997, 91, 231–241, doi:10.1016/S0092-8674(00)80405-5. 9346240
[147]
del Peso, L.; Gonzalez-Garcia, M.; Page, C.; Herrera, R.; Nunez, G. Interleukin-3-induced phosphorylation of bad through the protein kinase Akt. Science？1997, 278, 687–689, doi:10.1126/science.278.5338.687. 9381178
[148]
Cardone, M.H.; Roy, N.; Stennicke, H.R.; Salvensen, G.S.; Franke, T.F.; Stanbridge, E.; Frisch, S.; Reed, J.C. Regulation of cell death protease caspase-9 by phosphorylation. Science？1998, 282, 1318–1321, doi:10.1126/science.282.5392.1318. 9812896
[149]
Zha, J.; Harada, H.; Yang, E.; Jockel, J.; Korsmeyer, S.J. Serine phosphorylation of death agonist Bad in response to survival factor results in binding to 14-3-3 not Bcl-xL. Cell？1996, 87, 619–628, doi:10.1016/S0092-8674(00)81382-3. 8929531
Mancini, M.; Nicholson, D.W.; Roy, S.; Thornberry, N.A.; Peterson, E.P.; Casciola-Rosen, L.A.; Rosen, A. The caspase-3 precursor has a cytosolic and mitochondrial distribution: implications for apoptotic signaling. J. Cell Biol.？1998, 140, 1485–1495, doi:10.1083/jcb.140.6.1485. 9508780
[155]
Krajewski, S.; Krajewska, M.; Ellerby, L.M.; Welsh, K.; Xie, Z.; Deveraus, Q.L.; Salvesen, G.S.; Bredesen, D.E.; Rosenthal, R.E.; Fiskum, G.; Reed, J.C. Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia. Proc. Natl. Acad. Sci. USA？1999, 96, 5752–5757, doi:10.1073/pnas.96.10.5752. 10318956
[156]
Zou, H.; Li, Y.; Liu, X.; Wang, X. An Apaf-1-cytochrome c multimeric complex is functional apoptosome that activates procaspase-9. J. Biol. Chem.？1999, 274, 11549–11556, doi:10.1074/jbc.274.17.11549. 10206961
[157]
Li, H.; Zhu, H.; Xu, C-J.; Yuan, J. Cleavage of Bid by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell？1998, 94, 491–501. 9727492
[158]
Robertson, J. D.; Enoksson, M.; Suomela, M.; Zhivotovsky, B.; Orrenius, S. Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. J. Biol. Chem.？2002, 277, 29803–29809. 12065594
[159]
LaCasse, E.C.; Baird, S.; Korneluk, R.G.; MacKenzie, A.E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene？1998, 17, 3247–3259. 9916987
[160]
Holcik, M. The IAP proteins. Trends Gen.？2002, 18, 537–538, doi:10.1016/S0168-9525(02)02743-9.
[161]
Deveraux, Q.L.; Roy, N.; Stennicke, H.R.; Van Arsdale, T.; Zhou, Q.; Srinivasula, S.M.; Alnemri, E.S.; Salvesen, G.S.; Reed, J.C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J.？1998, 17, 2215–2223. 9545235
[162]
Hao, Y.; Sekine, K.; Kawabata, A; Nakamura, H.; Ishioka, T.; Ohata, H.; Katayama, R.; Hashimoto, C.; Zhang, X.; Noda, T.; Tsuruo, T.; Naito, M. Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function. Nat. Cell Biol.？2004, 6, 849–860. 15300255
[163]
Jiang, Y.; de Bruin, A.; Caldas, H.; Fangusaro, J.; Hayes, J.; Conway, E.M.; Robinson, M.L.; Altura, A. Essential role for survivin in early brain development. J. Neurosci.？2005, 25, 6962–6970. 16049172
[164]
Xu, D.G.; Korneluk, R.G.; Tamai, K.; Wigle, N.; Hakim, A.; MacKenzie, A.; Robertson, G.S. Distribution of neuronal apoptosis inhibitory protein-like immunoreactivity in the rat central nervous system. J. Comp. Neurol.？1997, 382, 247–259, doi:10.1002/(SICI)1096-9861(19970602)382:2<247::AID-CNE8>3.0.CO;2-3. 9183692
[165]
McPhail, L.T.; Vanderluit, J.L.; McBride, C.B.; Oschipok, L.W.; crocker, S.J.; Xu, D.; Thompson, C.S.; Liston, P.; Holcik, M.; Robertson, G.S.; Tetzlaff, W. Endogenous expression of inhibitor of apoptosis proteins in facial motoneurons of neonatal and adult rats following axotomy. Neuroscience？2003, 117, 567–575, doi:10.1016/S0306-4522(02)00742-X. 12617963
[166]
Roy, N.; Mahadevan, M.S.; McLean, M.; Shutler, G.; Yaraghi, Z.; Farahani, R.; Baird, S.; Besner-Johnston, A.; Lefebvre, C.; Kang, X.; Salih, M.; Aubry, H.; Tamai, K.; Guan, X.; Ioannou, P.; Crawford, T.O.; de Jong, P.J.; Surh, L.; Ikeda, J.-E.; Korneluk, R.G.; Mackenzie, A. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell？1995, 80, 167–178, doi:10.1016/0092-8674(95)90461-1. 7813013
[167]
Du, C.; Fang, M.; Li, Y.; Li, L.; Wang, X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell？2000, 102, 33–42, doi:10.1016/S0092-8674(00)00008-8. 10929711
[168]
Verhagen, A.M.; Ekert, P.G.; Pakusch, M.; Silke, J.; Connolly, L.M.; Reid, G.E.; Moritz, R.L.; Simpson, R.J.; Vaux, D.L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell？2000, 102, 43–53, doi:10.1016/S0092-8674(00)00009-X. 10929712
[169]
Suzuki, Y.; Imai, Y.; Nakayama, H.; Takahashi, K; Takio, K; Takahashi, R. A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol. Cell？2001, 8, 613–621, doi:10.1016/S1097-2765(01)00341-0. 11583623
[170]
Bogaerts, V.; Nuytemans, K.; Reumers, J.; Pals, R.; Engelborghs, S.; Pickut, B.; Corsmit, E.; Peeters, K.; Schymkowizt, J.; De Deyn, P.P.; Cras, P.; Rousseau, F.; Theuns, J.; Van Broeckhoven, C. Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson’s disease. Hum. Mut.？2008, 29, 832–840, doi:10.1002/humu.20713. 18401856
[171]
Simon-Sanchez, J.; Singleton, A.B. Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls. Hum. Mol. Gen.？2008, 17, 1988–1993, doi:10.1093/hmg/ddn096. 18364387
Mate, M.J.; Ortiz-Lombardia, M.; Boitel, B.; Haouz, A.; Tello, D.; Susin, S.A.; Penninger, J.; Kroemer, G.; Alzari, P.M. The crystal structure of the mouse apoptosis-inducing factor AIF. Nature Struct. Biol.？2002, 9, 442–446, doi:10.1038/nsb793. 11967568
[174]
Giaccia, A.J.; Kastan, M.B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Develop.？1998, 12, 2973–2983, doi:10.1101/gad.12.19.2973. 9765199
[175]
Maki, C.G.; Huibregtse, J.M.; Howley, P.M. In vivo ubiquitination and proteasome-mediated degradation of p53. Cancer Res.？1996, 56, 2649–2654. 8653711
[176]
Shieh, S-Y.; Ikeda, M.; Taya, Y.; Prives, C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell？1997, 91, 325–334. 9363941
[177]
Villunger, A.; Michalak, E.M.; Coultas, L.; Müllauer, F.; B？ck, G.; Ausserlechner, M.J.; Adams, J.M.; Strasser, A. p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa. Science？2003, 302, 1036–1038, doi:10.1126/science.1090072. 14500851
[178]
Erster, S.; Moll, U.M. Stress-induced p53 runs a transcription-independent death program. Biochem Biophys. Res. Comm.？2005, 331, 843–850, doi:10.1016/j.bbrc.2005.03.187. 15865940
[179]
Chipuk, J.E.; Kuwana, T.; Bouchier-hayes, L.; Droin, N.M.; Newmeyer, D.D.; Schuler, M.; Green, D.R. Direct activation of bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science？2004, 303, 1010–1014, doi:10.1126/science.1092734. 14963330
[180]
Leu, J. I-J.; Dumont, P.; Hafey, M.; Murphy, M.E.; George, D.L. Mitochondrial p53 activates Bak and causes disruption of a bak-Mcl1 complex. Nat. Cell Biol.？2004, 6, 443–450, doi:10.1038/ncb1123. 15077116
[181]
Aloyz, R.S.; Bamji, S.X.; Pozniak, C.D.; Toma, J.G.; Atwal, J.; Kaplan, D.R.; Miller, F.D. p53 is essential for developmental neuron death regulated by the TrkA and p75 neurotrophin receptors. J. Cell. Biol.？1998, 143, 1691–1703, doi:10.1083/jcb.143.6.1691. 9852160
[182]
Martin, L.J.; Kaiser, A.; Yu, J.W.; Natale, J.E.; Al-Abdulla, N.A. Injury-induced apoptosis of neurons in adult brain is mediated by p53-dependent and p53-independent pathways and requires Bax. J. Comp. Neurol.？2001, 433, 299–311. 11298357
[183]
Morrison, R.S.; Kinoshita, Y.; Johnson, M.D.; Guo, W.; Garden, G.A. p53-dependent cell death signaling in neurons. Neurochem. Res.？2003, 28, 15–27, doi:10.1023/A:1021687810103. 12587660
[184]
Pozniak, C.D.; Radinovic, S.; Yang, A.; McKeon, F.; Kaplan, D.R.; Miller, F.D. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science？2000, 289, 304–306. 10894779
[185]
Li, L.; Liu, F.; Salmonsen, R.A.; Turner, T.K.; Litofsky, N.S.; Di Cristofano, A.; Pandolfi, P.P.; Jones, S.N.; Recht, L.D.; Ross, A.H. PTEN in neural precursor cells: regulation of migration, apoptosis, and proliferation. Mol. Cell. Neurosci.？2002, 20, 21–29. 12056837
[186]
Desagher, S.; Osen-Sand, A.; Nichols, A.; Eskes, R.; Montessuit, S.; Lauper, S.; Maundrell, K.; Antonsson, B.; Martinou, J-C. Bid-induced conformational change of bax is responsible for mitochondrial cytochrome c release during apoptosis. J. Cell. Biol.？1999, 144, 891–901, doi:10.1083/jcb.144.5.891. 10085289
[187]
Troy, C.M.; Friedman, J. E.; Friedman, W. J. Mechanisms of p75-mediated death of hippocampal neurons. Role of caspases. J. Biol. Chem.？2002, 277, 34295–34302. 12097334
[188]
Martin, L.J.; Chen, K.; Liu, Z. Adult motor neuron apoptosis is mediated by nitric oxide and Fas death receptor linked by DNA damage and p53 activation. J. Neurosci.？2005, 25, 6449–6459, doi:10.1523/JNEUROSCI.0911-05.2005. 16000635
[189]
Lucas, D.R.; Newhouse, J.P. The toxic effect of sodium L-glutamate on the inner layers of the retina. Arch. Ophthal.？1957, 58, 193–201, doi:10.1001/archopht.1957.00940010205006.
[190]
Olney, J.W. Glutamate-induced neuronal necrosis in the infant mouse hypothalamus. An electron microscopic study. J. Neuropathol. Exp. Neurol.？1971, 30, 75–90. 5542543
Martin, L.J. The apoptosis-necrosis cell death continuum in CNS development, injury and disease: contributions and mechanisms. In Neuroprotection; Lo, E.H., Marwah, J., Eds.; Prominent Press: Scottsdale, AR, USA, 2002; pp. 379–412.
[193]
Martin, L.J.; Sieber, F.E.; Traystman, R.J. Apoptosis and necrosis occur in separate neuronal populations in hippocampus and cerebellum after ischemia and are associated with alterations in metabotropic glutamate receptor signaling pathways. J. Cereb. Blood Flow. Metab.？2000, 20, 153–167, doi:10.1097/00004647-200001000-00020. 10616804
[194]
Martin, L.J. Excitotoxicity. In Encyclopedia of Neuroscience; Adelman, G., Smith, B.H., Eds.; Elsevier Science: Amsterdam, The Netherland, 2004. CD-ROM.
[195]
Reynolds, I.J. Mitochondrial membrane potential and the permeability transition in excitotoxicity. Ann. N.Y. Acad. Sci.？1999, 893, 33–41, doi:10.1111/j.1749-6632.1999.tb07816.x. 10672228
[196]
Sonkusare, S.K.; Kaul, C.L.; Ramarao, P. Dementia of Alzheimer’s disease and other neurodegenerative disorders- memantine, a new hope. Pharma. Res.？2005, 51, 1–17, doi:10.1016/j.phrs.2004.05.005.
[197]
Gwag, B.J.; Koh, J.Y.; DeMaro, J.A.; Ying, H.S.; Jacquin, M.; Choi, D.W. Slowly triggered excitotoxicity occurs by necrosis in cortical cultures. Neuroscience？1997, 77, 393–401, doi:10.1016/S0306-4522(96)00473-3. 9472399
[198]
Kure, S.; Tominaga, T.; Yoshimoto, T.; Tada, K.; Narisawa, K. Glutamate triggers internucleosomal DNA cleavage in neuronal cells. Biochem. Biophys. Res. Commun.？1991, 179, 39–45, doi:10.1016/0006-291X(91)91330-F. 1679329
[199]
Ankarcrona, M.; Dypbukt, J.M.; Bonfoco, E.; Zhivotovsky, B.; Orrenius, S.; Lipton, S.A.; Nicotera, P. Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function. Neuron？1995, 15, 961–973, doi:10.1016/0896-6273(95)90186-8. 7576644
[200]
Simonian, N.A.; Getz, R.L.; Leveque, J.C.; Konradi, C.; Coyle, J. T. Kainate induces apoptosis in neurons. Neuroscience？1996, 74, 675–683, doi:10.1016/0306-4522(96)00141-8. 8884764
[201]
Dessi, F.; Charriaut-Marlangue, C.; Khrestchatisky, M.; Ben-Ari, Y. Glutamate-induced neuronal death is not a programmed cell death in cerebellar culture. J. Neurochem.？1993, 60, 1953–1955, doi:10.1111/j.1471-4159.1993.tb13427.x. 8097239
Miller, T.M.; Moulder, K.L.; Knudson, C.M.; Creedon, D.J.; Deshmukh, M.; Korsmeyer, S.J.; Johnson, E.M., Jr. Bax deletion further orders the cell death pathway in cerebellar granule cells and suggests a caspase-independent pathway to cell death. J. Cell. Biol.？1997, 139, 205–217, doi:10.1083/jcb.139.1.205. 9314540
[204]
Dargusch, R.; Piasecki, D.; Tan, S.; Liu, Y.; Schubert, D. The role of Bax in glutamate-induced nerve cell death. J. Neurochem.？2001, 76, 295–301. 11146002
[205]
Johnson, M.D.; Kinoshita, Y.; Xiang, H.; Ghatan, S.; Morrison, R.S. Contribution of p53-dependent caspase activation to neuronal cell death declines with neuronal maturation. J. Neurosci.？1999, 19, 2996–3006. 10191317
[206]
Tenneti, L.; Lipton, S.A. Involvement of activated caspase-3-like proteases in N-methyl-D-aspartate-induced apoptosis in cerebrocortical neurons. J. Neurochem.？2001, 74, 134–142, doi:10.1046/j.1471-4159.2000.0740134.x.
[207]
Simons, M.; Beinroth, S.; Gleichmann, M.; Liston, P.; Korneluk, R.G.; MacKenzie, A.E.; Bahr, M.; Klockgether, T.; Robertson, G.S.; Weller, M.; Schulz, J.B. Adenovirus-mediated gene transfer of inhibitors of apoptosis proteins delays apoptosis in cerebellar granule neurons. J. Neurochem.？1999, 72, 292–301. 9886081
[208]
van Lookeren Campagne, M.; Lucassen, P.J.; Vermeulen, J.P.; Balázs, R. NMDA and kainate induced internucleosomal DNA cleavage associated with both apoptotic and necrotic cell death in the neonatal rat brain. Eur. J. Neurosci.？1995, 7, 1627–1640, doi:10.1111/j.1460-9568.1995.tb01158.x. 7551189
[209]
Holcik, M.; Thompson, C.S.; Yaraghi, Z.; Lefebvre, C.A.; MacKenzie, A.E.; Korneluk, R.G. The hippocampal neurons of neuronal apoptosis inhibitory protein 1 (NAIP1)-deleted mice display increased vulnerability to kainic acid-induced injury. Proc. Natl. Acad. Sci. USA？1999, 97, 2286–2290.
[210]
Schreiber, S.S.; Tocco, G.; Najm, I.; Thompson, R.F.; Baudry, M. Cycloheximide prevents kainate-induced neuronal death and c-fos expression in adult rat brain. J. Mol. Neurosci.？1993, 4, 149–159, doi:10.1007/BF02782498. 8292488
[211]
Leppin, C.; Finiels-Marlier, F.; Crawley, J.N.; Montpied, P.; Paul, S.M. Failure of a protein synthesis inhibitor to modify glutamate receptor-mediated neurotoxicity in vivo. Brain Res.？1992, 581, 168–170, doi:10.1016/0006-8993(92)90359-H. 1379868
[212]
Lok, J.; Martin, L.J. Rapid subcellular redistribution of Bax precedes caspase-3 and endonuclease activation during excitotoxic neuronal apoptosis in rat brain. J. Neurotrauma？2002, 19, 815–828, doi:10.1089/08977150260190410. 12184852
[213]
Mueller, D.; Shamblott, M.J.; Fox, H.F.; Gearhart, J.D.; Martin, L.J. Transplanted human embryonic germ cell-derived neural stem cells replace neurons and oligodendrocytes in the forebrain of neonatal mice with excitotoxic brain damage. J. Neurosci. Res.？2005, 82, 592–608, doi:10.1002/jnr.20673. 16247803
[214]
Al-Abdulla, N.A.; Portera-Cailliau, C.; Martin, L.J. Occipital cortex ablation in adult rat causes retrograde neuronal death in the lateral geniculate nucleus that resembles apoptosis. Neuroscience？1998, 86, 191–209, doi:10.1016/S0306-4522(98)00014-1. 9692754
[215]
Yang, Y.; Xie, Y.; Chai, H.; Fan, M.; Liu, S.; Liu, H.; Bruce, I.; Wu, W. Microarray analysis of gene expression patterns in adult spinal motoneurons after different types of axonal injuries. Brain Res.？2006, 1075, 1–12, doi:10.1016/j.brainres.2005.12.060. 16460709
[216]
Al-Abdulla, N.A.; Martin, L.J. Apoptosis of retrogradely degenerating neurons occurs in association with the accumulation of perikaryal mitochondria and oxidative damage to the nucleus. Am. J. Pathol.？1998, 153, 447–456, doi:10.1016/S0002-9440(10)65588-5. 9708805
[217]
Fujikawa, D.G. Confusion between neuronal apoptosis and activation of programmed cell death mechanisms in acute necrotic insults. Trends Neurosci.？2000, 23, 410–411, doi:10.1016/S0166-2236(00)01601-5. 10941188
[218]
Ishimaru, M.J.; Ikonomidou, C.; Tenkova, T.I.; Der, T.C.; Dikranian, K; Sesma, M.A.; Olney, J.W. Distinguishing excitotoxic from apoptotic neurodegeneration in the developing rat brain. J. Comp. Neurol.？1999, 408, 461–476, doi:10.1002/(SICI)1096-9861(19990614)408:4<461::AID-CNE2>3.0.CO;2-9. 10340498
[219]
Sloviter, R.S. Apoptosis: a guide for the perplexed. Trends Pharmacol. Sci.？2002, 23, 19–24, doi:10.1016/S0165-6147(00)01867-8. 11804647
Zhu, C.; Wang, X.; Xu, F.; Bahr, B.A.; Shibata, M.; Uchiyama, Y.; Hagberg, H.; Blomgren, K. The influence of age on apoptotic and other mechanisms of cell death after cerebral hypoxia-ischemia. Cell Death Differ.？2005, 12, 162–176, doi:10.1038/sj.cdd.4401545. 15592434
[222]
Sheldon, R.A.; Hall, J.J.; Noble, L.J.; Ferriero, D.M. Delayed cell death in neonatal mouse hippocampus from hypoxia-ischemia is neither apoptotic nor necrotic. Neurosci. Lett.？2001, 304, 165–168, doi:10.1016/S0304-3940(01)01788-8. 11343828
[223]
Wei, L.; Ying, D.J.; Cui, L.; Lungsdorf, J.; Yu, S.P. Necrosis, apoptosis and hybrid death in the cortex and thalamus after barrel cortex ischemia in rats. Brain Res.？2004, 1022, 54–61, doi:10.1016/j.brainres.2004.06.080. 15353213
[224]
Martin, L.J. Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J. Neuropathol. Exp. Neurol.？1999, 58, 459–471. 10331434
[225]
Zoccolella, S.; Santamato, A.; Lamberti, P. Current and emerging treatments for amyotrophic lateral sclerosis. Neuropsychiatr. Dis. Treat.？2009, 5, 577–595. 19966906
[226]
Katzman, R. Education and the prevalence of dementia and Alzheimer’s disease. Neurology？1993, 43, 13–20, doi:10.1212/WNL.43.1_Part_1.13. 8423876
[227]
Evans, D.A.; Funkenstein, H.H.; Albert, M.S.; Scherr, P.A.; Cook, N.R.; Chown, M.J.; Hebert, L.E.; Hennekens, C.H.; Taylor, J.O. Prevalence of Alzheimer’s disease in a community population of older persons. Higher than previously reported. JAMA？1989, 262, 2551–2556. 2810583
[228]
McKhann, G.; Drachman, D.; Folstein, M.; Katzman, R.; Price, D.; Stadlan, E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services task force on Alzheimer’s disease. Neurology？1984, 34, 939–944, doi:10.1212/WNL.34.7.939. 6610841
[229]
Olshansky, S.J.; Carnes, B.A.; Cassel, C.K. The aging of the human species. Sci. Am.？1993, 268, 46–52, doi:10.1038/scientificamerican0493-46. 8446881
[230]
Minati, L.; Edginton, T.; Bruzzone, M.G.; Giaccone, G. Current concepts in Alzheimer's disease: A multidisciplinary review. Am. J. Alz. Dis. Other Demen.？2009, 24, 95–121, doi:10.1177/1533317508328602.
[231]
Chartier-Harlin, M.-C.; Crawford, F.; Houlden, H.; Warren, A.; Hughes, D.; Fidani, L.; Goate, A.; Rossor, M.; Roques, P.; Hardy, J.; Mullan, M. Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature？1991, 353, 844–846, doi:10.1038/353844a0. 1944558
[232]
Tilley, L.; Morgan, K.; Kalsheker, N. Genetic risk factors for Alzheimer’s disease. J. Clin. Pathol. Mol. Pathol.？1998, 51, 293–304, doi:10.1136/mp.51.6.293.
[233]
Goate, A.; Chartier-Harlin, M.-.C.; Mullan, M.; Brown, J.; Crawford, F.; Fidani, L.; Giuffra, L.; Haynes, A.; Irving, N.; James, L.; Mant, R.; Newton, P.; Rooke, K.; Roques, P.; Talbot, C.; Pericak-Vance, M.; Roses, A.; Williamson, R.; Rossor, M.; Owen, M.; Hardy, J. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature？1991, 349, 704–706. 1671712
[234]
Naruse, S.; Igarashi, S.; Kobayashi, H.; Aoki, K.; Inuzuka, T.; Kaneko, K.; Shimizu, T.; Iihara, K.; Kojima, T.; Miyatake, T.; Tsuji, S. Mis-sense mutation Val->Ile in exon 17 of amyloid precursor protein gene in Japanese familial Alzheimer's disease. Lancet？1991, 337, 978–979. 1678058
[235]
Campion, D.; Flaman, J.M.; Brice, A.; Hannequin, D.; Dubois, B.; Martin, C.; Moreau, V.; Charbonnier, F.; Didierjean, O.; Tardieu, S.; Penet, C.; Puel, M.; Pasquier, F.; Ledoze, F.; Bellis, G.; Calenda, A.; Heilig, R.; Martinez, M.; Mallet, J.; Bellis, M.; Clergetdarpoux, F.; Agid, Y.; Frebourg, T. Mutations of the presenilin 1 gene in families with early-onset Alzheimer's disease. Hum. Mol. Genet.？1995, 4, 2373–2377, doi:10.1093/hmg/4.12.2373. 8634712
Kalaria, R.N. Dementia comes of age in the developing world. Lancet？2003, 361, 888–889, doi:10.1016/S0140-6736(03)12783-3. 12648963
[238]
Roses, A.D. Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu. Rev. Med.？1996, 47, 387–400, doi:10.1146/annurev.med.47.1.387. 8712790
[239]
Whitehouse, P.J.; Price, D.L.; Struble, R.G.; Clark, A.W.; Coyle, J.T.; DeLong, M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science？1982, 215, 1237–1239, doi:10.1126/science.7058341. 7058341
[240]
Gomez-Isla, T.; Price, J.L.; McKeel, D.W., Jr.; Morris, J.C.; Growdon, J.H.; Hyman, B.T. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J. Neurosci.？1996, 16, 4491–4500. 8699259
[241]
Mouton, P.R.; Martin, L.J.; Calhoun, M.E.; Dal Forno, G.; Price, D.L. Cognitive decline strongly correlates with cortical atrophy in Alzheimer’s disease. Neurobiol. Aging？1998, 19, 371–377, doi:10.1016/S0197-4580(98)00080-3. 9880038
[242]
West, M.J.; Kawas, C.H.; Martin, L.J.; Troncoso, J.C. The CA1 region of the human hippocampus is a hot spot in Alzheimer’s disease. Ann. N.Y. Acad. Sci.？2000, 908, 255–259. 10911964
[243]
Pelvig, D.P.; Pakkenberg, H.; Regeur, L.; Oster, S.; Pakkenberg, B. Neocortical glial cell numbers in Alzheimer's disease. A stereological study. Dement. Geriatr. Cogn. Disord.？2003, 16, 212–219, doi:10.1159/000072805. 14512716
[244]
Braak, H.; Braak, E. Neuropathological staging of Alzheimer’s disease-related changes. Acta Neuropathol.？1991, 82, 239–259, doi:10.1007/BF00308809. 1759558
[245]
Kermer, P.; Liman, J; Weishaupt, J.H.; Bahr, M. Neuronal apoptosis in neurodegenerative diseases: from basic research to clinical application. Neurodeg. Dis.？2004, 1, 9–19, doi:10.1159/000076665.
[246]
Smale, G.; Nichols, N.R.; Brady, D.R.; Finch, C.E.; Horten, W.E., Jr. Evidence for apoptotic cell death in Alzheimer's disease. Exp. Neurol.？1995, 133, 225–230, doi:10.1006/exnr.1995.1025. 7544290
[247]
Anderson, A.J.; Su, J.H.; Cotman, C.W. DNA damage and apoptosis in Alzheimer's disease: colocalization with c-jun immunoreactivity, relationship to brain area, and effect of postmortem delay. J. Neurosci.？1996, 16, 1710–1719. 8774439
[248]
Adamec, E.; Vonsattel, J.P.; Nixon, R.A. DNA strand breaks in Alzheimer's disease. Brain Res.？1999, 849, 67–77, doi:10.1016/S0006-8993(99)02004-1. 10592288
[249]
Stadelmann, C.; Deckwerth, T.L.; Srinivasan, A.; Bancher, C.; Brock, W.; Lassmann, H. Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am. J. Pathol.？1999, 155, 1459–1466, doi:10.1016/S0002-9440(10)65460-0. 10550301
[250]
Lucassen, P.J.; Chung, W.C.J.; Kamphorst, W.; Swaab, D.F. DNA damage distribution in the human brain as shown by in situ end labeling; area-specific differences in aging and Alzheimer's disease in the absence of apoptotic morphology. J. Neuropathol. Exp. Neurol.？1997, 56, 887–900, doi:10.1097/00005072-199708000-00007. 9258259
[251]
Su, J.H.; Zhao, M.; Anderson, A.J.; Srinivasan, A.; Cotman, C.W. Activated caspase-3 expression in Alzheimer's and aged control brain: correlation with Alzheimer pathology. Brain Res.？2001, 898, 350–357, doi:10.1016/S0006-8993(01)02018-2. 11306022
Gastard, M.C.; Troncoso, J.C.; Koliatsos, V.E. Caspase activation in the limbic cortex of subjects with early Alzheimer's disease. Ann. Neurol.？2003, 54, 393–398, doi:10.1002/ana.10680. 12953274
[254]
Pompl, P.N.; Yemul, S.; Xiang, Z.; Ho, L.; Haroutunian, V.; Purohit, D.; Mohs, R.; Pasinetti, G.M. Caspase gene expression in the brain as a function of the clinical progression of Alzheimer's disease. Arch. Neurol.？2003, 60, 369–376, doi:10.1001/archneur.60.3.369. 12633148
[255]
Rohn, T.T.; Rissman, R.A.; Davis, M.C.; Kim, Y.E.; Cotman, C.W.; Head, E. Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. Neurobiol. Dis.？2002, 11, 341–354, doi:10.1006/nbdi.2002.0549. 12505426
[256]
Guo, H.; Albrecht, S.; Bourdeau, M.; Petzke, T.; Bergeron, C.; LeBlanc, A.C. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer’s disease. Am. J. Pathol.？2004, 165, 523–531, doi:10.1016/S0002-9440(10)63317-2. 15277226
[257]
Selznick, L.A.; Holtzman, D.M.; Han, B.H.; Gokden, M.; Srinivasan, A.N.; Johnson, E.M., Jr.; Roth, K.A. In situ immunodetection of neuronal caspase-3 activation in Alzheimer's disease. J. Neuropath. Exp. Neurol.？1999, 58, 1020–1026, doi:10.1097/00005072-199909000-00012.
[258]
Lesuisse, C.; Martin, L.J. Immature and mature neurons engage different apoptotic mechanisms involving caspase-3 and the mitogen-activated protein kinase pathway. J. Cereb. Blood Flow Metabol.？2002, 22, 935–950.
[259]
Shimohama, S.; Tanino, H.; Fujimoto, S. Differential subcellular localization of caspase family protein in the adult rat brain. Neurosci. Lett.？2001, 315, 125–128, doi:10.1016/S0304-3940(01)02336-9. 11716979
[260]
Yan, X.X.; Najbauer, J.; Woo, C.C.; Dashtipour, K.; Ribak, C.E.; Leon, M. Expression of active caspase-3 in mitotic and postmitotic cells or rat forebrain. J. Comp. Neurol.？2001, 433, 4–22, doi:10.1002/cne.1121. 11283945
Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science？2002, 297, 353–356, doi:10.1126/science.1072994. 12130773
[263]
Kosik, K.S.; Joachim, C.L.; Selkoe, D.J. Microtubule-associated protein tau is a major antigenic component of paired helical filaments in Alzheimer's disease. Proc. Natl. Acad. Sci. USA？1986, 83, 4044–4048, doi:10.1073/pnas.83.11.4044. 2424016
[264]
Sze, C.-I.; Bi, H.; Kleinschmidt-DeMasters, B.K.; Filley, C.M.; Martin, L.J. N-Methyl-D-aspartate receptor subunit proteins and their phosphorylation status are altered selectively in Alzheimer’s disease. J. Neurol. Sci.？2001, 182, 151–159, doi:10.1016/S0022-510X(00)00467-6. 11137521
[265]
Kemp, J.A.; McKernan, R.M. NMDA receptor pathways as drug targets. Nat. Neurosci.？2002, 5, 1039–1042. (suppl), doi:10.1038/nn936. 12403981
[266]
Mattson, M.P.; Cheng, B.; Davis, D.; Bryant, K.; Lieberburg, I.; Rydel, R.E. β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci.？1993, 12, 376–389.
[267]
Reddy, P.H.; Beal, M.F. Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer’s disease. Trends Mol. Med.？2008, 14, 45–53, doi:10.1016/j.molmed.2007.12.002. 18218341
[268]
DeKosky, S.T.; Scheff, S.W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol.？1990, 27, 457–464, doi:10.1002/ana.410270502. 2360787
[269]
Terry, R.D.; Masliah, E.; Salmon, D.P.; Butters, N.; DeTeresa, R.; Hill, R.; Hansen, L.A.; Katsman, R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol.？1991, 30, 572–580, doi:10.1002/ana.410300410. 1789684
[270]
Martin, L.J.; Pardo, C.A.; Cork, L.C.; Price, D.L. Synaptic pathology and glial responses to neuronal injury precede the formation of senile plaques and amyloid deposits in the aging cerebral cortex. Am. J. Pathol.？1994, 145, 1358–1381. 7992840
[271]
Sze, C.-I.; Troncoso, J.C.; Kawas, C.; Mouton, P.; Price, D.L.; Martin, L.J. Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer’s disease. J. Neuropathol. Exp. Neurol.？1997, 56, 933–994, doi:10.1097/00005072-199708000-00011. 9258263
[272]
Selkoe, D.J. Alzheimer's disease is a synaptic failure. Science？2002, 298, 789–791, doi:10.1126/science.1074069. 12399581
[273]
Yankner, B.A.; Dawes, L.R.; Fisher, S.; Villa-Komaroff, L.; Oster-Granite, M.L.; Neve, R.L. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. Science？1989, 245, 417–420, doi:10.1126/science.2474201. 2474201
[274]
Younkin, S.G. Evidence that Abeta 42 is the real culprit in Alzheimer's disease. Ann. Neurol.？1995, 37, 287–288, doi:10.1002/ana.410370303. 7695227
[275]
Fath, T.; Eidenmuller, J.; Brandt, R. Tau-mediated cytotoxicity in a pseudohyperphosphorylation model of Alzheimer's disease. J. Neurosci.？2002, 22, 9733–9741. 12427828
[276]
Rapoport, M.; Dawson, H.N.; Binder, L.I.; Vitek, M.P.; Ferreira, A. Tau is essential to β-amyloid-induced neurotoxicity. Proc. Natl. Acad. Sci. USA？2002, 99, 6364–6369, doi:10.1073/pnas.092136199. 11959919
[277]
Anandatheerthavarada, H.K.; Biswas, G.; Robin, M.A.; Avadhani, N.G. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer’s amyloid precursor protein impairs mitochondrial function in neuronal cells. J. Cell Biol.？2003, 161, 41–54, doi:10.1083/jcb.200207030. 12695498
[278]
Devi, L.; Prabhu, B.M.; Galati, D.F.; Avadhani, N.G.; Anandatheerthavarada, H.K. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer’s disease brain is associated with mitochondrial dysfunction. J. Neurosci.？2006, 26, 9057–9068, doi:10.1523/JNEUROSCI.1469-06.2006. 16943564
[279]
Manczak, M.; Anekonda, T.S.; Henson, E.; Park, B.S.; Quinn, J.; Reddy, P.H. Mitochondria are a direct site of Aβ accumulation in Alzheimer’s disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum. Mol. Gen.？2006, 15, 1437–1449, doi:10.1093/hmg/ddl066.
[280]
Caspersen, C.; Wang, N.; Yao, J.; Sosunov, A.; Chen, X.; Lustbader, J.W.; Xu, H.W.; Stern, D.; McKhann, G.; Yan, S.D. Mitochondrial Aβ: a potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J.？2005, 19, 2040–2041. 16210396
[281]
Lustbader, J.W.; Cirilli, M.; Lin, C.; Xu, H.W.; Takuma, K.; Wang, N.; Caspersen, C.; Chen, X.; Pollak, S.; Chaney, M.; Trinchese, F.; Liu, S.; Gunn-Moore, F.; Lue, L.-F.; Walker, D.G.; Kuppsamy, P.; Zewier, Z.L.; Arancio, O.; Stern, D.; Yan, S.S.; Wu, H. ABAD directly links Aβ to mitochondrial toxicity in Alzheimer’s disease. Science？2004, 304, 448–452. 15087549
[282]
Du, H.; Guo, L.; Fang, F.; Chen, D.; Sosunov, A.A.; McKhann, G.M.; Yan, Y.; Wang, C.; Zhang, H.; Molkentin, J.D.; Gunn-Moore, F.J.; Vonsattel, J.P.; Aranico, O.; Chen, J.X.; Yan, S.D. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer’s disease. Nat. Med.？2008, 14, 1097–1105, doi:10.1038/nm.1868. 18806802
[283]
Duyckaerts, C.; Potier, M.C.; Delatour, B. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol.？2008, 115, 5–38. 18038275
[284]
Irizarry, M.C.; McNamara, M.; Fedorchak, K.; Hsiao, K.; Hyman, B.T. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol.？1997, 56, 965–973, doi:10.1097/00005072-199709000-00002. 9291938
[285]
Irizarry, M.C.; Soriano, F.; McNamara, M.; page, K.J.; Schenk, D.; Games, D.; Hyman, B.T. Aβ deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyoid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci.？1997, 17, 7053–7059. 9278541
[286]
Takeuchi, A.; Irizarry, M.C.; Duff, K.; Saido, T.C.; Hsiao-Ashe, K.; Hasegawa, M.; Mann, D.M.A.; Hyman, B.T.; Iwatsubo, T. Age-related amyloid β deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid β precursor protein Swedish mutant is not associated with global neuronal loss. Am. J. Pathol.？2000, 157, 331–339, doi:10.1016/S0002-9440(10)64544-0. 10880403
[287]
Calhoun, M.E.; Wiederhold, K.H.; Abramowski, D.; Phinney, A.L.; Probst, A.; Sturchler-Pierrat, C.; Staufenbiel, M.; Sommer, B.; Jucker, M. Neuron loss in APP transgenic mice. Nature？1998, 395, 755–756, doi:10.1038/27351. 9796810
[288]
Selznick, L.A.; Holtzman, D.M.; Han, B.H.; Gokden, M.; Srinivasan, A.N.; Johnson, E.M., Jr.; Roth, K.A. In situ immunodetection of neuronal caspase-3 activation in Alzheimer's disease. J. Neuropath. Exp. Neurol.？1999, 58, 1020–1026, doi:10.1097/00005072-199909000-00012. 10499444
[289]
Yang, D.-S.; Kumar, A.; Stavrides, P.; Peterson, J.; Peterhoff, C.M.; Pawlik, M.; Levy, E.; Cataldo, A.M.; Nixon, R.A. Neuronal apoptosis and autophagy cross talk in aging PS/APP mice, a model of Alzheimer’s disease. Am. J. Pathol.？2008, 173, 665–681, doi:10.2353/ajpath.2008.071176. 18688038
[290]
Oddo, S.; Caccamo, A.; Shepherd, J.D.; Murphy, M.P.; Golde, T.E.; Kayed, R.; Metherate, R.; Mattson, M.P.; Akbari, Y.; LaFerla, F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron？2003, 39, 409–421, doi:10.1016/S0896-6273(03)00434-3. 12895417
[291]
LaFerla, F.M.; Hall, C.K.; Ngo, L.; Jay, G. Extracellular deposition of β-amyloid upon p53-dependent neuronal cell death in transgenic mice. J. Clin. Invest.？1996, 98, 1626–1632, doi:10.1172/JCI118957. 8833912
[292]
Zhang, Y.; McLaughlin, R.; Goodyer, C.; LeBlanc, A. Selective cytotoxicity of intracellular amyloid β peptide1-42 through p53 and Bax in cultured primary human neurons. J. Cell Biol.？2002, 156, 519–529, doi:10.1083/jcb.200110119. 11815632
[293]
Loo, D.T.; Copani, A.; Pike, C.J.; Whittemore, E.R.; Walencewicz, A.J.; Cotman, C.W. Apoptosis is induced by β-amyloid in cultured central nervous system neurons. Proc. Natl. Acad. Sci. USA？1993, 90, 7951–7955, doi:10.1073/pnas.90.17.7951. 8367446
[294]
Behl, C.; Davis, J.B.; Klier, F.G.; Schubert, D. Amyloid beta peptide induces necrosis rather than apoptosis. Brain Res.？1994, 645, 253–264, doi:10.1016/0006-8993(94)91659-4. 8062088
[295]
Casley, C.S.; Land, J.M.; Sharpe, M.A.; Clark, J.B.; Duchen, M.R.; Canevari, L. β-amyloid fragment 25-35 causes mitochondrial dysfunction in primary cortical neurons. Neurobiol. Dis.？2002, 10, 258–267, doi:10.1006/nbdi.2002.0516. 12270688
[296]
Duker, N.J.; Sperling, J.; Soprano, K.J.; Druin, D.P.; Davis, A.; Ashworth, R. β-Amyloid protein induces the formation of purine dimers in cellular DNA. J. Cell Biochem.？2001, 81, 393–400, doi:10.1002/1097-4644(20010601)81:3<393::AID-JCB1053>3.0.CO;2-5. 11255222
[297]
Kuperstein, F; Yavin, E. ERK activation and nuclear translocation in amyloid-beta peptide- and iron-stressed neuronal cell cultures. Eur. J. Neurosci.？2002, 16, 44–54, doi:10.1046/j.1460-9568.2002.02056.x. 12153530
[298]
Morishima, Y.; Gotoh, Y.; Zieg, J.; Barrett, T.; Takano, H.; Flavell, R.; Davis, R.J.; Shirasaki, Y.; Greenberg, M.E. β-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J. Neurosci.？2001, 21, 7551–7560. 11567045
[299]
Yaar, M.; Zhai, S.; Fine, R.E.; Eisenhauer, P.B.; Arble, B.L.; Stewart, K.B.; Gilchrest, B.A. Amyloid β binds trimers as well as monomers of the 75-kDa neurotrophin receptor and activates receptor signaling. J. Biol. Chem.？2002, 277, 7720–7725, doi:10.1074/jbc.M110929200. 11756426
[300]
Nakagawa, T.; Zhu, H.; Morishima, N.; Li, E.; Xu, J.; Yankner, B.A.; Yuan, J. Caspase-12 mediates endoplasmic reticulum-specific apoptosis and cytotoxicity by amyloid-β. Nature？2000, 403, 98–103, doi:10.1038/47513. 10638761
Culmsee, C.; Zhu, X.; Yu, Q.S.; Chan, S.L.; Camandola, S.; Guo, Z.; Greig, N.H.; Mattson, M.P. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J. Neurochem.？2001, 77, 220–228, doi:10.1046/j.1471-4159.2001.t01-1-00220.x. 11279278
[303]
Ma, L.; Ohyagi, Y.; Miyoshi, K.; Sakae, N.; Motomaura, K.; Taniwaki, T.; Furuya, H.; Takeda, K.; Tabira, T.; Kira, J. Increase in p53 protein levels by presenilin 1 gene mutations and its inhibition by secretase inhibitors. J. Alz. Dis.？2009, 16, 565–575.
[304]
Giovanni, A.; Keramaris, E.; Morris, E.J.; Hou, S.T.; O'Hare, M.; Dyson, N.; Robertson, G.S.; Slack, R.S.; Park, D.S. E2F1 mediates death of β-amyloid-treated cortical neurons in a manner independent of p53 and dependent on Bax and caspase 3. J. Biol. Chem.？2000, 275, 11553–11560, doi:10.1074/jbc.275.16.11553. 10766769
[305]
Paradis, E.; Douillard, H.; Koutroumanis, M.; Goodyer, C.; LeBlanc, A. Amyloid β peptide of Alzheimer's disease downregulates Bcl-2 and upregulates Bax expression in human neurons. J. Neurosci.？1997, 16, 7533–7539.
[306]
Weidemann, A.; Paliga, K.; Durrwang, U.; Reinhard, F.B.M.; Schuckert, O.; Evin, G.; Masters, C.L. Proteolytic processing of the Alzheimer’s disease amyloid precursor protein within its cytoplasmic domain by caspase-like proteases. J. Biol. Chem.？1999, 274, 5823–5829. 10026204
[307]
LeBlanc, A.; Liu, H.; Goodyer, C.; Bergeron, C.; Hammond, J. Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer’s disease. J. Biol. Chem.？1999, 274, 23426–23436. 10438520
[308]
Gervais, F.G.; Xu, D.; Robertson, G.S.; Vaillancourt, J.P.; Zhu, Y.; Huang, J.; LeBlanc, A.; Smith, D.; Rigby, M.; Shearman, M.S.; Clarke, E.E.; Zheng, H.; van der Ploeg, L.H.; Ruffolo, S.C.; Thornberry, N.A.; Xanthoudakis, S.; Zamboni, R.J.; Roy, S.; Nicholson, D.W. Involvement of caspases in proteolytic cleavage of Alzheimer’s amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell？1999, 97, 395–406, doi:10.1016/S0092-8674(00)80748-5. 10319819
[309]
Nikolaev, A.; McLaughlin, T.; O’Leary, D.D.M.; Tessier-Lavign, M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature？2009, 457, 981–989, doi:10.1038/nature07767. 19225519
[310]
Passer, B.J.; Pellegrini, L.; Vito, P.; Ganjei, J.K.; D'Adamio, L. Interaction of Alzheimer’s presenilin-1 and presenilin-2 with Bcl-X(L). A potential role in modulating the threshold of cell death. J. Biol. Chem.？1999, 274, 24007–24013. 10446169
[311]
Kim, T.-W.; Pettingell, W.H.; Jung, Y.-K.; Kovacs, D.M.; Tazi, R.E. Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protein. Science？1997, 277, 373–376. 9219695
[312]
Bursztajn, S.; DeSouza, R.; McPhie, D.L.; Berman, S.A.; Shioi, J.; Robakis, N.K.; Neve, R.L. Overexpression in neurons of human presenilin-1 or a presenilin-1 familial Alzheimer disease mutant does not enhance apoptosis. J. Neurosci.？1998, 18, 9790–9799. 9822738
[313]
Gamliel, A.; Teicher, C.; Hartmann, T.; Beyreuther, K.; Stein, R. Overexpression of wild-type presenilin 2 or its familial Alzheimer's disease-associated mutant does not induce or increase susceptibility to apoptosis in different cells. Neuroscience？2003, 117, 119–128, doi:10.1016/S0306-4522(02)00826-6. 12605898
[314]
Chan, S.L.; Culmsee, C.; Haughey, N.; Klapper, W.; Mattson, M.P. Presenilin-1 mutations sensitize neurons to DNA damage-induced death by a mechanism involving perturbed calcium homeostasis and activation of calpains and caspase-12. Neurobiol. Dis.？2002, 11, 2–19, doi:10.1006/nbdi.2002.0542. 12460542
[315]
Van Den Eeden, S.K.; Tanner, C.M.; Bernstein, A.L.; Fross, R.D.; Leimpeter, A.; Bloch, D.A.; Nelson, L.M. Indicence of Parkinson's disease: variations by age, gender and race ethnicity. Am. J. Epidemol.？2003, 157, 1015–1022, doi:10.1093/aje/kwg068.
[316]
Jankovic, J. Parkinson’s disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry？2008, 79, 368–376, doi:10.1136/jnnp.2007.131045. 18344392
[317]
Lowe, J.; Lennox, G.; Leigh, P.N. Disorders of movement and system degeneration. In Greenfields Neuropathology; Graham, D.I., Lantos, P.L., Eds.; London: Arnold, 1997; pp. 281–366.
[318]
Braak, H.; Del Tredici, K.; Rüb, U.; d Vos, R.A.I.; Jansen Steur, E.N.H.; Braak, E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging？2003, 24, 197–211, doi:10.1016/S0197-4580(02)00065-9. 12498954
[319]
Goedert, M. Alpha-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci.？2001, 2, 492–501, doi:10.1038/35081564. 11433374
Paisán-Ru？z, C.; Jain, S.; Whitney Evans, E.; Gilks, W.P.; Simón, J.; van der Brug, M.; López de Munain, A.; Aparicio, S.; Mart？nez-Gil, A.; Khan, N.; Johnson, J.; Ruiz Martinez, J.; Nicholl, D.; Marti Carrera, I.; Saénz Peňa, A.; de Silva, R.; Lees, A.; Mart？-Massó, J.F.; Pérez-Tur, J.; Wood, N.W.; Singleton, A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron？2004, 44, 595–600. 15541308
[331]
Zimprich, A.; Biskup, S.; Leitner, P.; Lichtner, P.; Farrer, M.; Lincoln, S.; Kachergus, J.; Hulihan, M.; Uitti, R.J.; Calne, D.B.; Stoessi, J.; Pfeiffer, R.F.; Patenge, N.; Carballo Carbajal, I.; Vieregge, P.; Asmus, F.; Müller-Myhsok, B.; Dickson, D.W.; Meitinger, T.; Storm, T.M.; Wszolek, Z.K.; Gasser, T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron？2004, 44, 601–607, doi:10.1016/j.neuron.2004.11.005. 15541309
[332]
Ramirez, A.; Heimbach, A.; grundemann, J.; Stiller, B.; Hampshire, D.; Cid, L.P.; Goebel, I.; Mubaidin, A,F.; Wriekat, A.-L.; Roeper, J.; Al-Din, A.; Hillmer, A.M.; Karsak, M.; Liss, B.; Woods, C.G.; Behrens, M.I. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Gen.？2006, 38, 1184–1191, doi:10.1038/ng1884.
[333]
Lesuisse, C.; Martin, L.J. Long-term culture of mouse cortical neurons as a model for neuronal development, aging, and death. J. Neurobiol.？2002, 51, 9–23, doi:10.1002/neu.10037. 11920724
[334]
Maroteaux, L.; Campanelli, J.T.; Scheller, R.H. Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminals. J. Neurosci.？1988, 8, 2804–2815. 3411354
[335]
Murphy, D.D.; Rueter, S.M.; Trojanowski, J.Q.; Lee, V.M.Y. Synucleins are developmentally expressed, and α-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J. Neurosci.？2000, 20, 3214–3220. 10777786
[336]
Nakamura, K.; Nemani, V.M.; Wallender, E.K.; Kaehlcke, K.; Ott, M.; Edwards, R.H. Optical reporters for the conformation of α-synuclein reveal a specific interaction with mitochondria. J. Neurosci.？2008, 28, 12305–12317. 19020024
Gurevicine, I.; Gurevicius, K.; Tanila, H. Role of α-synuclein in synaptic glutamate release. Neurobiol. Dis.？2007, 28, 83–89, doi:10.1016/j.nbd.2007.06.016. 17689254
[339]
Liu, S.; Fa, M.; Ninan, I.; Trinchese, F.; Dauer, W.; Aranico, O. α-Synuclein involvement in hippocampla synaptic plasticity: role of NO, cGMP, cGK and CAMKII. Eur. J. Neurosci.？2007, 25, 3583–3596, doi:10.1111/j.1460-9568.2007.05569.x. 17610578
[340]
Fortin, D.L.; Nemani, V.M.; Voglmaier, S.M.; Anthony, M.D.; Ryan, T.A.; Edwards, R.H. Neural activity control the synaptic accumulation of α-synuclein. J. Neurosci.？2005, 25, 10913–10921. 16306404
Gallardo, G.; Schluter, O.M.; Sudhof, T.C. A molecular pathway of neurodegeneration linking α-synuclein to ApoE and Aβ peptides. Nat. Neurosci.？2008, 11, 301–308. 18297066
[343]
Serpell, L.C.; Berriman, J.; Jakes, M.; Goedert, M.; Crowther, R.A. Fiber diffraction of synthetic alpha synuclein filaments shows amyloid-like cross-beta conformation. Proc. Natl. Acad. Sci. USA？2000, 97, 4897–4902, doi:10.1073/pnas.97.9.4897. 10781096
[344]
Conway, K.A.; Lee, S.J.; Rochet, J.C.; Ding, T.T.; Williamson, R.E.; Lansbury, P.T., Jr. Acceleration of oligomerization, not fibrilization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA？2000, 97, 571–576, doi:10.1073/pnas.97.2.571. 10639120
[345]
Caughey, B.; Lansbury, P.T. Protofibrils, pores, fibril, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci.？2003, 26, 267–298, doi:10.1146/annurev.neuro.26.010302.081142. 12704221
[346]
Hsu, L.J.; Sagara, Y.; Arroyo, A.; Rockenstein, E.; Sisk, A.; Mallory, M.; Wong, J.; Takenouchi, T.; Hashimoto, M.; Masliah, E. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol.？2000, 157, 401–410, doi:10.1016/S0002-9440(10)64553-1. 10934145
[347]
Junn, E.; Mouradian, M.M. Human α-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett.？2002, 320, 146–150, doi:10.1016/S0304-3940(02)00016-2. 11852183
Ischiropoulos, H. Oxidative modification of alpha-synuclein. Ann. N.Y. Acad. Sci.？2003, 991, 93–100. 12846977
[352]
Wilkinson, K.D.; Lee, K.M.; Deshpande, S.; Duerken-Hughes, P.; Boss, J.M.; Pohl, J. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl terminal hydrolase. Science？1989, 246, 670–673. 2530630
[353]
Hershko, A.; Ciechanover, A. The ubiquitin system. Annu. Rev. Biochem.？1998, 67, 425–479, doi:10.1146/annurev.biochem.67.1.425. 9759494
[354]
Lansbury, P.T., Jr.; Brice, A. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr. Opin. Cell Biol.？2002, 14, 653–660, doi:10.1016/S0955-0674(02)00377-0. 12231362
[355]
McNaught, K.S.; Mytilineou, C.; Jnobaptiste, R.; Yabut, J.; Shahidharan, P.; Jennert, P.; Olanow, C.W. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J. Neurochem.？2002, 81, 301–306, doi:10.1046/j.1471-4159.2002.00821.x. 12064477
[356]
Imai, Y.; Takahashi, R. How do Parkin mutations result in neurodegeneration? Curr. Opin. Neurobiol.？2004, 14, 384–389, doi:10.1016/j.conb.2004.04.002. 15194120
[357]
Hattori, N.; Matsumine, H.; Asakawa, S.; Kitada, T.; Yoshino, H.; Elibol, B; brookes, A.J.; Yamamura, Y.; Kobayashi, T.; Wang, M.; Yoritaka, A.; Minoshima, S.; Shimizu, N.; Mizuno, Y. Point mutations (Thr240Arg and Gln311Stop) in the Parkin gene. Biochem. Biophys. Res. Commun.？1998, 249, 754–758, doi:10.1006/bbrc.1998.9134. 9731209
[358]
Beilina, A.; Van Der Brug, M.; Ahmad, R.; Kesavapany, S.; Miller, D.W.; Petsko, G.A.; Cookson, M.R. Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability. Proc. Natl. Acad. Sci. USA？2005, 102, 5703–5708, doi:10.1073/pnas.0500617102. 15824318
[359]
Silvestri, L.; Caputo, V.; Bellacchio, E.; Atorino, L.; Dallapiccola, B.; Valente, E.M.; Casari, G. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Hum. Mol. Genet.？2005, 14, 3477–3492, doi:10.1093/hmg/ddi377. 16207731
[360]
Unoki, M.; Nakamura, Y. Growth-suppressive effects of BPOZ and RGR2, two genes involved in the PTEN signaling pathway. Oncogene？2001, 20, 4457–4465, doi:10.1038/sj.onc.1204608. 11494141
[361]
Taymans, J-M.; Van den Haute, C.; Baekelandt, V. Distribution of PINK1 and LRRK2 in rat and mouse brain. J. Neurochem.？2006, 98, 951–961, doi:10.1111/j.1471-4159.2006.03919.x. 16771836
[362]
Weihofen, A.; Thomas, K.J.; Ostazewski, B.L.; Cooksen, M.R.; Selkoe, D.J. Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry？2009, 48, 2045–2052. 19152501
[363]
Deng, H.; Jankovic, J.; Guo, Y.; Xie, W.; Le, W. Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem. Biophys. Res. Commun.？2005, 337, 1133–1138, doi:10.1016/j.bbrc.2005.09.178. 16226715
[364]
Marongiu, R.; Spencer, B.; Crews, L.; Adame, A.; Patrick, C.; Trejo, M.; dallapiccola, B.; Valente, E.M.; Masliah, E. Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson’s disease by disturbing calcium flux. J. Neurochem.？2009, 108, 1561–1574, doi:10.1111/j.1471-4159.2009.05932.x. 19166511
[365]
Wilson, M.A.; Collins, J.L.; Hod, Y.; Ringe, D.; Petsko, G.A. The 1.1-A resolution crystal structure of DJ-1, the protein mutated in autosomal recessive early onset Parkinson's disease. Proc. Natl. Acad. Sci. USA？2003, 100, 9256–9261, doi:10.1073/pnas.1133288100. 12855764
[366]
Shang, H.; Lang, D.; Jean-Marc, B.; Kaelin-Lang, A. Localization of DJ-1 mRNA in the mouse brain. Neurosci. Lett.？2004, 367, 273–277, doi:10.1016/j.neulet.2004.06.002. 15337248
[367]
Canet-Aviles, R.M.; Wilson, M.A.; Miller, D.W.; Ahmad, R.; McLendon, C.; Bandyopadhyay, S.; Baptista, M.J.; Ringe, D.; Petsko, G.A.; Cookson, M.R. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl. Acad. Sci. USA？2004, 101, 9103–9108, doi:10.1073/pnas.0402959101. 15181200
[368]
Miller, D.W.; Ahmad, R.; Hague, S.; Baptista, M.J.; Canet-Aviles, R.; McLendon, C.; Carter, D.M.; Zhu, P.P.; Stadler, J.; Chandran, J.; Klinefelter, G.R.; Blackstone, C.; Cookson, M.R. L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system. J. Biol. Chem.？2003, 278, 36588–36595. 12851414
[369]
Takahashi-Niki, K.; Niki, T.; Taira, T.; Iguchi-Ariga, S.M.; Ariga, H. Reduced anti-oxidative stress activities of DJ-1 mutants found in Parkinson's disease patients. Biochem. Biophys. Res. Commun.？2004, 320, 389–397, doi:10.1016/j.bbrc.2004.05.187. 15219840
[370]
Galter, D.; Westerlund, M.; Carmine, A.; Lindqvist, E.; Sydow, O.; Olson, L. LRRK2 expression linked to dopamine-innervated areas. Ann. Neurol.？2006, 59, 714–719, doi:10.1002/ana.20808. 16532471
Ho, C. C-Y.; Rideout, H.J.; Ribe, E.; Troy, C.M.; Dauer, W.T. The Parkinson’s disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J. Neurosci.？2009, 29, 1011–1016. 19176810
[374]
Tatton, N.A.; MaClean-Fraser, A.; Tatton, W.G.; Perl, D.P.; Olnanow, C.W. A fluorescent double-labeling method to detect and confirm apoptotic nuclei in Parkinson’s disease. Ann. Neurol.？1998, 44, S142–S148, doi:10.1002/ana.410440721. 9749586
[375]
Jellinger, K.A. Is there apoptosis in Lewy body disease? Acta Neuropathol.？1999, 97, 413–415, doi:10.1007/s004010051006. 10208282
[376]
Wüllner, U.; Kornhuber, J.; Weller, M.; Schulz, J.B.; Loschmann, P.A.; Riederer, P.; Klockgether, T. Cell death and apoptosis regulating proteins in Parkinson’s disease- a cautionary note. Acta Neuropathol.？1999, 97, 408–412, doi:10.1007/s004010051005. 10208281
[377]
Anglade, P.; Vyas, S.; Javoy-Agid, F.; Herrero, M.T.; Michel, P.P.; Marguez, J.; Mouatt-Prigent, A.; Ruberg, M.; Hirsch, E.C.; Agid, Y. Apoptosis and autophagy in nigral neurons of patients with Parkinson’s disease. Histol. Histopathol.？1997, 12, 25–31. 9046040
[378]
Martin, L.J.; Liu, Z.; Troncoso, J.C.; Price, D.L. Neuronal cell death in human neurodegenerative diseases and their animal/cell models. In Apoptosis in Health and Disease; Holcik, M., LaCasse, E., Korneluk, R., MacKenzie, A., Eds.; Cambridge University Press: Cambridge, UK, 2005; pp. 242–315.
[379]
Tompkins, M.M.; Basgall, E.J.; Zamrini, E.; Hill, W.D. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigra neurons. Am. J. Pathol.？1997, 150, 119–131. 9006329
[380]
Ginsberg, S.D.; Hemby, S.E.; Mufson, E.J.; Martin, L.J. Cell and tissue microdissection in combination with genomic and proteomic profiling. In Neuroanatomical Tract-Tracing 3, Molecules, Neurons, and Systems; Zaborszky, L., Wouterlood, F.G., Lanciego, J.L., Eds.; Springer: New York, NY, USA, 2006; pp. 109–141.
[381]
Martin, L.J; Liu, Z.; Chen, K.; Price, A.C.; Pan, Y.; Swaby, J.A.; Golden, W.C. Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase-1 transgenic mice: mechanisms of mitochondriopathy and cell death. J. Comp. Neurol.？2007, 500, 20–46, doi:10.1002/cne.21160. 17099894
[382]
Goldberg, M.S.; Fleming, S.M.; Palacino, J.J.; Capedam, C.; Lam, H.A.; Bhatnagar, A.; Meloni, E.G.; Wu, N.; Ackerson, L.C.; Klapstein, G.J.; Gajendiram, M.; Roth, B.L.; Chesselet, M.F.; Maidment, N.T.; Levine, M.S.; Shen, J. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem.？2003, 278, 43628–43635. 12930822
[383]
Perez, F.A.; Palmiter, R.D. Parkin-deficient mice are not a robust model of parkinsonism. Proc. Natl. Acad. Sci. USA？2005, 102, 2174–2179, doi:10.1073/pnas.0409598102. 15684050
[384]
Palacino, J.J.; Sagi, D.; Goldberg, M.S.; Krauss, S.; Motz, C.; Wacker, M.; Klose, J.; Shen, J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem.？2004, 279, 18614–18622, doi:10.1074/jbc.M401135200. 14985362
Chen, L.; Cagniard, B.; Mathews, T.; Jones, S.; Koh, H.C.; Ding, Y.; Carvey, P.M.; Ling, Z.; Kang, U.J.; Zhuang, X. Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J. Biol. Chem.？2005, 280, 21418–21426, doi:10.1074/jbc.M413955200. 15799973
[387]
Goldberg, M.S.; Pisani, A.; Haburcak, M.; Vortherms, T.A.; Kitada, Y.; Costa, C.; Tong, Y.; Martella, G.; Tscherter, A.; Martins, A.; Bernardi, G.; Roth, B.L.; Pothos, E.N.; Calabresi, P.; Shen, J. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial parkinsonism-linked gene DJ-1. Neuron？2005, 45, 489–496, doi:10.1016/j.neuron.2005.01.041. 15721235
[388]
Gispert, S.; Del Turco, D.; Garrett, L.; Chen, A.; Bernard, D.J.; Hamm-Clement, J.; Korf, H.W.; Deller, T.; Braak, H.; Auburger, G.; Nussbaum, R.L. Transgenic mice expressing mutant A53T human alpha-synuclein show neuronal dysfunction in the absence or aggregate formation. Mol. Cell. Neurosci.？2003, 24, 419–429, doi:10.1016/S1044-7431(03)00198-2. 14572463
[389]
Kahle, P.J.; Neumann, M.; Ozmen, L.; Muller, V.; Jacobsen, H.; Schindzielorz, A.; Okochi, M.; Leimer, U.; van der Putten, H.; Probst, A.; Kremmer, E.; Kretzschmar, H.A.; Haassm, C. Subcellular localization of wild-type and Parkinson’s disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci.？2000, 20, 6365–6373. 10964942
[390]
Lee, M.K.; Stirling, W.; Xu, Y.; Xu, X.; Qui, D.; Mandir, A.S.; Dawson, T.M.; Copeland, N.G.; Jenkins, N.A.; Price, D.L. Human α-synuclein-harboring familial Parkinson’s disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA？2002, 99, 8968–8973, doi:10.1073/pnas.132197599. 12084935
[391]
Masliah, E.; Rockenstein, E.; Veinbergs, I.; Mallory, M.; Hashimoto, M.; Takeda, A.; Sagara, Y.; Sisk, A.; Mucke, L. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science？2000, 287, 1265–1269, doi:10.1126/science.287.5456.1265. 10678833
[392]
Richfield, E.K.; Thiruchelvam, M.J.; Cory-Slechta, D.A.; Wuetzer, C.; Gainetdinov, R.R.; Caron, M.G.; Di Monte, D.A.; Federoff, H.J. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp. Neurol.？2002, 175, 35–48, doi:10.1006/exnr.2002.7882. 12009758
[393]
van der Putten, H.; Wiederhold, K-H.; Probst, A.; Barbieri, S.; Mistl, C.; Danner, S.; Kauffmann, S.; Hofele, K.; Spooren, W.P.; Ruegg, M.A.; Lin, S.; Caroni, P.; Sommer, B.; Tolnay, M.; Bilbe, G. Neuropathology in mice expressing human α-synuclein. J. Neurosci.？2000, 20, 6021–6029. 10934251
[394]
Wakamatsu, M.; Ishii, A.; Iwata, S.; Sakagami, J.; Ukai, Y.; Ono, M.; Kanbe, D.; Muramatsu, S-i.; Kabayashi, K.; Iwatsubo, T.; Yoshimoto, M. Selective loss of nigral dopamine neurons induced by overexpression of truncated human α-synuclein. Neurobiol. Aging？2008, 29, 547–585.
Lieberman, A.R. The axon reaction: a review of the principal features of perikaryal responses to axon injury. Int. Rev. Neurobiol.？1971, 14, 49–124. 4948651
[397]
Poon, H.F.; Frasier, M.; Shreve, N.; Calabrese, V.; Wolozin, B.; Butterfield, D.A. Mitochondrial associated metabolic proteins are selectively oxidized in A30P α-synuclein transgenic mice- a model of familial Parkinson’s disease. Neurobiol. Dis.？2005, 18, 492–498, doi:10.1016/j.nbd.2004.12.009. 15755676
[398]
Turnbull, S.; Tabner, B.J.; El-Agnaf, O.M.; Moore, S.; Davies, Y.; Allsop, D. Alpha-synuclein implicated in Parkinson’s disease catalyses the formation of hydrogen peroxide in vitro. Free Radic. Biol. Med.？2001, 30, 1163–1170, doi:10.1016/S0891-5849(01)00513-5. 11369507
Paxinou, E.; Chen, Q.; Weisse, M.; Giasson, B.I.; Norris, E.H.; Rueter, S.M.; Trojanowski, J.Q.; Lee, VM-Y.; Ischiropoulos, H. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci.？2001, 21, 8053–8061. 11588178
[401]
Souza, J.M.; Giasson, B.I.; Chen, Q.; Lee, VM-Y.; Ischiropoulos, H. Dityrosine cross-linking promotes formation of stable α-synuclein polymers. J. Biol. Chem.？2000, 365, 18344–18349.
[402]
Chen, K.; Northington, F.J.; Martin, L.J. Inducible nitric oxide synthase is present in motor neuron mitochondria and Schwann cells and contributes to disease mechanisms in ALS mice. Brain Struct. Funct.？2010. in press.
[403]
Rowland, L.P.; Shneider, N.A. Amyotrophic lateral sclerosis. N. Engl. J. Med.？2001, 344, 1688–1700, doi:10.1056/NEJM200105313442207. 11386269
[404]
Sathasivam, S.; Ince, P.G.; Shaw, P.J. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropathol. Appl. Neurobiol.？2001, 27, 257–274, doi:10.1046/j.0305-1846.2001.00332.x. 11532157
[405]
Stephens, B.; Guiloff, R.J.; Navarrete, R.; Newman, P.; Nikhar, N.; Lewis, P. Widespread loss of neuronal populations in spinal ventral horn in sporadic motor neuron disease. A morphometric study. J. Neurol. Sci.？2006, 244, 41–58, doi:10.1016/j.jns.2005.12.003. 16487542
[406]
Maekawa, S.; Al-Sarraj, S.; Kibble, M.; Landau, S.; Parnavelas, J.; Cotter, D.; Everall, I.; Leigh, P.N. Cortical selective vulnerability in motor neurons disease: a morphometric study. Brain？2004, 127, 1237–1251, doi:10.1093/brain/awh132. 15130949
Chow, C.Y.; Lander, J.E.; Bergren, S.K.; Sapp, P.C.; Grant, A.E.; Jones, J.M.; Everett, L.; Lenk, G.M.; McKenna-Yasek, D.M.; Weisman, L.S.; Figlewicz, D.; Brown, R.H.; Meisler, M.H. Deleterious variants of FIG4, a phosphoinositade phosphatase, in patients with ALS. Am. J. Human Gen.？2009, 84, 85–88, doi:10.1016/j.ajhg.2008.12.010.
[410]
Sasaki, S.; Iwata, M. Ultrastructural changes of synapses of Betz cell in patients with amyotrophic lateral sclerosis. Neurosci. Lett.？1999, 268, 29–32, doi:10.1016/S0304-3940(99)00374-2. 10400070
Comi, G.P.; Bordoni, A.; Salani, S.; Franeschina, L.; Sciacco, M.; Prelle, A.; Fortunato, F.; Zeviani, M.; Napoli, L.; Bresolin, N.; Moggio, M.; Ausenda, C.D.; Taanman, J.W.; Scarlato, G. Cytochrome c oxidase subunit I microdeletion in a paitent with motor neuron disease. Ann. Neurol.？1998, 43, 110–116, doi:10.1002/ana.410430119. 9450776
[413]
Borthwick, G.M.; Taylo, R.W.; Walls, T.J.; Tonska, K.; Taylor, G.A.; Shaw, P.J.; Ince, P.G.; Turnbull, D.M. Motor neuron disease in a patient with a mitochondrial tRNAIle mutation. Ann. Neurol.？2006, 59, 570–574, doi:10.1002/ana.20758. 16358336
[414]
Soong, N.W.; Hinton, D.R.; Cortopassi, G.; Arnheim, N. Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. Nat. Genet.？1992, 2, 318–323, doi:10.1038/ng1292-318. 1303287
[415]
Corral-Debrinski, M.; Horton, T.; Lott, M.T.; Shoffner, J.M.; Beal, M.F.; Wallace, D.C. Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Nat. Genet.？1992, 2, 324–329, doi:10.1038/ng1292-324. 1303288
Brown, M.R.; Sullivan, P.G.; Geddes, J.W. Synaptic mitochondria are more susceptible to Ca2+ overload than nonsynaptic mitochondria. J. Biol. Chem.？2006, 281, 11658–11668, doi:10.1074/jbc.M510303200. 16517608
[422]
Rothstein, J.D.; Martin, L.J.; Kuncl, R.W. Decreased glutamate transport by brain and spinal cord in amyotrophic lateral sclerosis. N. Engl. J. Med.？1992, 326, 1464–1468, doi:10.1056/NEJM199205283262204. 1349424
[423]
Rothstein, J.D.; Van Kammen, M.; Levey, A.I.; Martin, L.J.; Kuncl, R.W. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol.？1995, 38, 73–84, doi:10.1002/ana.410380114. 7611729
[424]
Heath, P.R.; Tomkins, J.; Ince, P.G.; Shaw, P.J. Quantitative assessment of AMPA receptor mRNA in human spinal motor neurons isolated by laser capture microdissection. NeuroReport？2002, 13, 1753–1757, doi:10.1097/00001756-200210070-00012. 12395117
[425]
Kwak, S.; Kawahara, Y. Deficient RNA editing of GluR2 and neuronal death in amyotrophic lateral sclerosis. J. Mol. Med.？2005, 83, 110–120, doi:10.1007/s00109-004-0599-z. 15624111
[426]
Chang, D.T.W.; Reynolds, I.J. Mitochondrial trafficking and morphology in healthy and injured neurons. Prog. Brain Res.？2006, 80, 241–268.
[427]
Hansson, M.J.; Mansson, R.; Morota, S.; Uchino, H.; Kallur, T.; Sumi, T.; Ishii, N.; Shimazu, M.; Keep, M.F.; Jegorov, A.; Elmer, E. Calcium-induced generation of reactive oxygen species in brain mitochondria is mediated by permeability transition. Free Radic. Biol. Med.？2008, 45, 284–294, doi:10.1016/j.freeradbiomed.2008.04.021. 18466779
[428]
Bergmann, F.; Keller, B.U. Impact of mitochondrial inhibition on excitability and cytosolic Ca2+ levels in brainstem motoneurones. J. Physiol.？2004, 555, 45–59, doi:10.1113/jphysiol.2003.053900. 14660707
[429]
Beal, M.F. Oxidatively modified protein in aging and disease. Free Radic. Biol. Med.？2002, 32, 797–803, doi:10.1016/S0891-5849(02)00780-3. 11978481
[430]
Ferrante, R.J.; Browne, S.E.; Shinobu, L.A.; Bowling, A.C.; Baik, M.J.; MacGarvey, U.; Kowall, N.W.; Brown, R.H., Jr.; Beal, M.F. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem.？1997, 69, 2064–2074. 9349552
[431]
Abe, K.; Pan, L-H.; Watanabe, M.; Kato, T.; Itoyama, Y. Induction of nitrotyrosine-like immunoreactivity in the lower motor neuron of amyotrophic lateral sclerosis. Neurosci. Lett.？1995, 199, 152–154. 8584246
[432]
Beal, M.F.; Ferrante, R.J.; Browne, S.E.; Matthews, R.T.; Kowall, N.W.; Brown, R.H., Jr. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann. Neurol.？1997, 42, 644–654, doi:10.1002/ana.410420416. 9382477
[433]
Sasaki, S.; Warita, H.; Abe, K.; Iwata, M. Inducible nitric oxide synthase (iNOS) and nitrotyrosine immunoreactivity in the spinal cords of transgenic mice with mutant SOD1 gene. J. Neuropathol. Exp. Neurol.？2001, 60, 839–846. 11556540
[434]
Browne, S.E.; Bowling, A.C.; Baik, M.J.; Gurney, M.; Brown, R.H., Jr; Beal, M.F. Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis. J. Neurochem.？1998, 71, 281–287. 9648876
[435]
Borthwick, G.M.; Johnson, M.A.; Ince, P.G.; Shaw, P.J.; Turnbul, D.M. Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann. Neurol.？1999, 46, 787–790, doi:10.1002/1531-8249(199911)46:5<787::AID-ANA17>3.0.CO;2-8. 10553999
[436]
Vielhaber, S.; Kunz, D.; Winkler, K.; Wiedemann, F.R.; Kirches, E.; Feistner, H.; Heinze, H.J.; Elger, C.E.; Schubert, W.; Kunz, W.S. Mitochondrial DNA abnormalities in skeletal muscle of patients with sporadic amyotrophic lateral sclerosis. Brain？2000, 123, 1339–1348, doi:10.1093/brain/123.7.1339. 10869047
[437]
Soraru, G.; Vergani, L.; Fedrizzi, L.; D’Ascenzo, C.; Polo, A.; Bernazzi, B.; Angelini, C. Activities of mitochondrial complexes correlate with nNOS amount in muscle from ALS patients. Neuropath. Appl. Neurobiol.？2007, 33, 204–211, doi:10.1111/j.1365-2990.2006.00791.x.
[438]
Echaniz-Laguna, A.; Zoll, J.; Ponsot, E.; N’Guessan, B.; Tranchant, C.; Loeffler, J-P.; Lampert, E. Muscular mitochondrial function in amyotrophic lateral sclerosis is progressively altered as the disease develops: a temporal study in man. Exp. Neurol.？2006, 198, 25–30. 16126198
[439]
Martin, L.J.; Liu, Z. Opportunities for neuroprotection in ALS using cell death mechanism rationales. Drug Discov. Today？2004, 1, 135–143, doi:10.1016/j.ddtec.2004.08.005.
[440]
Martin, L.J. p53 is abnormally elevated and active in the CNS of patients with amyotrophic lateral sclerosis. Neurobiol. Dis.？2000, 7, 613–622, doi:10.1006/nbdi.2000.0314. 11114260
[441]
Yamazaki, M.; Esumi, E.; Nakani, I. Is motoneuronal death in amyotrophic lateral sclerosis apoptosis? Neuropathology？2005, 25, 381–387, doi:10.1111/j.1440-1789.2005.00648.x. 16382789
[442]
Martin, L.J.; Liu, Z. Injury-induced spinal motor neuron apoptosis is preceded by DNA single-strand breaks and is p53- and Bax-dependent. J. Neurobiol.？2002, 50, 181–197, doi:10.1002/neu.10026. 11810634
[443]
Fornai, F.; Longone, P.; Ferrucci, M.; Lenzi, P.; Isidoro, C.; Ruggieri, S.; Paparelli, A. Autophagy and amyotrophic lateral sclerosis. Autophagy？2008, 4, 527–530. 18367867
[444]
Turner, B.J.; Talbot, K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog. Neurobiol.？2008, 85, 94–134, doi:10.1016/j.pneurobio.2008.01.001. 18282652
[445]
McCord, J.M.; Fridovich, I. Superoxide dismutase, an enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem.？1969, 244, 6049–6055. 5389100
[446]
Rakhit, R.; Crow, J.P.; Lepock, J.R.; Kondejewski, L.H.; Cashman, N.R.; Chakrabartty, A. Monomeric Cu, Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic sclerosis. J. Biol. Chem.？2004, 279, 15499–15504, doi:10.1074/jbc.M313295200. 14734542
[447]
Ferri, A.; Cozzolino, M.; Crosio, C.; Nencini, M.; Casciati, A.; Gralla, E.B.; Rotilio, G.; Valentine, J.S.; Carri, M.T. Familial ALS-superoxide dismutases associate with mitochondria and shift their redox potentials. Proc. Natl. Acad. Sci. USA？2006, 103, 13860–13865, doi:10.1073/pnas.0605814103. 16945901
[448]
Estévez, A.G.; Crow, J.P.; Sampson, J.B.; Reiter, C.; Zhuang, Y.; Richardson, G.J.; Tarpey, L. ; Barbeito, M.M.; Beckman, J.S. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science？1999, 286, 2498–2500. 10617463
[449]
Flanagan, S.W.; Anderson, R.D.; Ross, M.A.; Oberley, L.W. Overexpression of manganese superoxide dismutase attenuates neuronal death in human cells expressing mutant (G37R) Cu/Zn-superoxide dismutase. J. Neurochem.？2002, 81, 170–177, doi:10.1046/j.1471-4159.2002.00812.x. 12067230
[450]
Bilsland, L.G.; Nirmalananthan, N.; Yip, J.; Greensmith, L.; Duhcen, M.R. Expression of mutant SOD1G93A in astrocytes induces functional deficits in motoneuron mitochondria. J. Neurochem.？2008, 107, 1271–1283, doi:10.1111/j.1471-4159.2008.05699.x. 18808448
[451]
Gurney, M.E.; Pu, H.; Chiu, A.Y.; Dal Canto, M.C.; Polchow, C.Y.; Alexander, D.D.; Caliendo, J.; Hentati, A.; Kwon, Y.W.; Deng, H.X.; Chen, W.; Zhai, P.; Sufit, R.L.; Siddique, T. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science？1994, 264, 1772–1775, doi:10.1126/science.8209258. 8209258
[452]
Dal Canto, M.C.; Gurney, M.E. Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am. J. Pathol.？1994, 145, 1271–1279. 7992831
[453]
Chang, Q.; Martin, L.J. Glycinergic innervation of motoneurons is deficient in amyotrophic lateral sclerosis mice: a confocal quantitative analysis. Am. J. Path.？2009, 174, 574–585, doi:10.2353/ajpath.2009.080557. 19116365
[454]
Bendotti, C.; Calvaresi, N.; Chiveri, L.; Prelle, A.; Moggio, M.; Braga, M.; Silani, V.; De Biasi, S. Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity. J. Neurol. Sci.？2001, 191, 25–33, doi:10.1016/S0022-510X(01)00627-X. 11676989
[455]
Wong, P.C.; Pardo, C.A.; Borchelt, D.R.; Lee, M.K.; Copeland, N.G.; Jenkins, N.A.; Sisodia, S.S.; Cleveland, D.W.; Price, D.L. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron？1995, 14, 1105–1116, doi:10.1016/0896-6273(95)90259-7. 7605627
[456]
Kong, J.; Xu, Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci.？1998, 18, 3241–3250. 9547233
Sasaki, S.; Warita, H.; Murakami, T.; Abe, K.; Iwata, M. Ultrastructural study of mitochondria in the spinal cord of transgenic mice with a G93A mutant SOD1 gene. Acta Neuropathol.？2004, 107, 461–474, doi:10.1007/s00401-004-0837-z. 15029445
Yim, M.B.; Kang, J-H.; Yim, H-S.; Kwak, H-S.; Chock, P.B.; Stadtman, E.R. A gain-of-function of an amyotrophic lateral sclerosis-associated Cu,Zn-superoxide dismutase mutant: an enhancement of free radical formation due to a decrease in Km for hydrogen peroxide. Proc. Natl. Acad. Sci. USA？1996, 93, 5709–5714, doi:10.1073/pnas.93.12.5709. 8650157
[462]
Kabashi, E.; Valdmanis, P.N.; Dion, P.; Rouleau, G.A. Oxidized/misfolded superoxide dismutase-1: the cause of all amyotrophic lateral sclerosis? Ann. Neurol.？2007, 62, 553–559, doi:10.1002/ana.21319. 18074357
[463]
Ezzi, S.A.; Urushitani, M.; Julien, J-P. Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J. Neurochem.？2007, 102, 170–178, doi:10.1111/j.1471-4159.2007.04531.x. 17394546
[464]
Liochev, S.I.; Fridovich, I. Mutant Cu,Zn superoxide dismutases and familial amyotrophic lateral sclerosis: evaluation of oxidative hypotheses. Free Radic. Biol. Med.？2003, 34, 1383–1389, doi:10.1016/S0891-5849(03)00153-9. 12757848
[465]
Pacher, P.; Beckman, J.S.; Liaudet, L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev.？2007, 87, 315–424, doi:10.1152/physrev.00029.2006. 17237348
[466]
Andrus, P.K.; Fleck, T.J.; Gurney, M.E.; Hall, E.D. Protein oxidative damage in a transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem.？1998, 71, 2041–2048. 9798929
[467]
Poon, H.F.; Hensley, K.; Thongboonkerd, V.; Merchant, M.L.; Lynn, B.C.; Pierce, W.M.; Klein, J.B.; Calabrese, V.; Butterfield, D.A. Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice- a model of familial amyotrophic lateral sclerosis. Free Radic. Biol. Med.？2005, 39, 435–462.
[468]
Higgins, C.M.J.; Jung, C.; Ding, H.; Xu, Z. Mutant Cu, Zn Superoxide dismutase that causes motoneuron degeneration is present in mitochondria in the CNS. J. Neurosci.？2002, 22, RC215:1–RC215:6.
[469]
Okado-Matsumoto, A.; Fridovich, I. Subcellular distribution of superoxide (SOD) in rat liver. J. Biol. Chem.？2001, 276, 38388–38393, doi:10.1074/jbc.M105395200. 11507097
Pasinelli, P.; Belford, M.E.; Lennon, N.; Bacskai, B.J.; Hyman, B.T.; Trotti, D.; Brown, R.H., Jr. Amyotrophic lateral sclerosis-associated SOD1 mutant protein bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron？2004, 43, 19–30, doi:10.1016/j.neuron.2004.06.021. 15233914
[472]
Vande Velde, C.; Miller, T.M.; Cashman, N.R.; Cleveland, D.W. Selective association of misfolded ALS-linked mutant SOD1 with the cytoplasmic face of mitochondria. Proc. Natl. Acad. Sci. USA？2008, 105, 4022–4027, doi:10.1073/pnas.0712209105. 18296640
[473]
Goldsteins, G.; Keksa-Goldsteine, V.; Ahtiniemi, T.; Jaronen, M.; Arens, E.; Akerman, K.; Chan, R.H.; Koistinaho, J. Deleterious role of superoxide dismutase in the mitochondrial intermembrane space. J. Biol. Chem.？2008, 283, 8446–8452, doi:10.1074/jbc.M706111200. 18171673
[474]
Higgins, C.M.; Jung, C.; Xu, Z. ALS-associated mutant SOD1G93A causes mitochondrial vacuolation by expansion of the intermembrane space and by involvement of SOD1 aggregation and peroxisomes. BMC Neurosci.？2003, 4, 16, doi:10.1186/1471-2202-4-16. 12864925
Jaiswal, M.K.; Keller, B.U. Cu/Zn superoxide dismutase typical for familial amyotrophic lateral sclerosis increases the vulnerability of mitochondria and perturbs Ca2+ homeostasis in SOD1G93A mice. Mol. Pharmacol.？2009, 75, 478–489, doi:10.1124/mol.108.050831. 19060114
[478]
Nguyen, K.T.; Garcia-Chacon, L.E.; Barrett, J.N.; Barrett, E.F.; David, G. The ψm depolarization that accompanies mitochondrial Ca2+ uptake is greater in mutant SOD1 than in wild-type mouse motor terminals. Proc. Natl. Acad. Sci. USA？2009, 106, 2007–2011, doi:10.1073/pnas.0810934106. 19174508
[479]
Sasaki, S.; Shibata, N.; Komori, T.; Iwata, M. iNOS and nitrotyrosine immunoreactivity in amyotrophic lateral sclerosis. Neurosci. Lett.？2000, 291, 44–48, doi:10.1016/S0304-3940(00)01370-7. 10962150
[480]
Kunz, W.S. Different metabolic properties of mitochondrial oxidative phosphorylation in different cell types- important implications for mitochondrial cytopathies. Exp. Physiol.？2003, 88.1, 149–154, doi:10.1113/eph8802512.
[481]
Keep, M.; Elmér, E.; Fong, K.S.K.; Csiszar, K. Intrathecal cyclosporin prolongs survival of late-stage ALS mice. Brain Res.？2001, 894, 327–331, doi:10.1016/S0006-8993(01)02012-1. 11251210
[482]
Karlsson, J.; Fong, K.S.; Hansson, M.J.; Elmer, E.; Csiszar, K.; Keep, M.F. Life span extension and reduced neuronal death after weekly intraventricular cyclosporine injections in the G93A transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosurg.？2004, 101, 128–137, doi:10.3171/jns.2004.101.1.0128. 15255263
[483]
Kirkinezos, I.G.; Hernandez, D.; Bradley, W.G.; Moraes, C.T. An ALS mouse model with a permeable blood-brain barrier benefits from systemic cyclosporine A treatment. J. Neurochem.？2004, 88, 821–826, doi:10.1046/j.1471-4159.2003.02181.x. 14756802
[484]
Bordet, T.; Buisson, B.; Michaud, M.; Drouot, C.; Galea, P.; Delaage, P.; Akentieva, N.P.; Evers, A.S.; Covey, D.F.; Ostuni, M.A.; lacapere, JJ-J.; Massaad, C.; Schmacher, M.; Steidl, E-M.; Maux, D.; Delaage, M.; Henderson, C.E.; Pruss, R.M. Identification and characterization of Cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J. Pharmacol. Exp. Ther.？2007, 322, 709–720. 17496168
[485]
Mills, C.; Makwana, M.; Wallace, A.; Benn, S.; Schmidt, H.; Tegeder, I.; Costigan, M.; Brown, R.H., Jr; Raivich, G.; Woolf, C. Ro5-4864 promotes neonatal motor neuron survival and nerve regeneration in adult rats. Eur. J. Neurosci.？2008, 27, 937–946, doi:10.1111/j.1460-9568.2008.06065.x. 18333964
[486]
Yan, L-J.; Sohal, R.S. Mitochondrial adenine nucleotide translocase is modified oxidatively during aging. Proc. Natl. Acad. Sci. USA？1998, 95, 12896–12901, doi:10.1073/pnas.95.22.12896. 9789011
[487]
Prokai, L.; Yan, L-J; Vera-Serrano, J.L.; Stevens, S.M., Jr; Forster, M.J. Mass spectrometry-based survey of age-associated protein carbonylation in rat brain mitochondria. J. Mass Spectrom.？2007, 42, 1583–1589, doi:10.1002/jms.1345. 18085547
[488]
Vieira, H.L.A.; Belzacq, A-S.; Haouzu, D.; Bernassola, F.; Cohen, I.; Jacotot, E.; Ferri, K.F.; Hamel, C.E.; Bartle, L.M.; Melino, G.; Brenner, C.; Goldmacher, V.; Kroemer, G. The adenine nucleotide translocator: a target of nitric oxide, peroxynitrite, and 4-hydroxynonenal. Oncogene？2001, 20, 4305–4316. 11466611
[489]
McStay, G.P.; Clarke, S.J.; Halestrap, A.P. Role of critical thiol groups on the matrix surface of the adenine nucleotide translocase in the mechanism of the mitochondrial permeability transition pore. Biochem. J.？2002, 367, 541–548, doi:10.1042/BJ20011672. 12149099
[490]
Costantini, P.; Belzacq, A-S.; Vieira, H.L.A.; Larochette, N.; de Pablo, M.A.; Zamzami, N.; Susin, S.A.; Brenner, C.; Kroemer, G. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene？2000, 19, 307–314. 10645010
[491]
García, N.; Martínez-Abundis, E.; Pavón, N.; Correa, F.; Chávez, E. Copper induces permeability transition through its interaction with the adenine nucleotide translocase. Cell Biol. Int.？2007, 31, 893–899, doi:10.1016/j.cellbi.2007.02.003. 17485229
[492]
Grimm, S.; Brdiczka, D. The permeability transition pore in cell death. Apoptosis？2007, 12, 841–855, doi:10.1007/s10495-007-0747-3. 17453156
[493]
Forte, M.; Gold, B.G.; Marracci, G.; Chaudhary, P.; Basso, E.; Johnsen, D.; Yu, Z.; Fowlkes, J.; Rahder, M.; Stern, K.; Bernardi, P.; Bourdette, D. Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Proc. Natl. Acad. Sci. USA？2007, 104, 7558–7563, doi:10.1073/pnas.0702228104. 17463082
[494]
Schinzel, A.C.; Takeuchi, O.; Huang, Z.; Fisher, J.K.; Zhou, Z.; Rubens, J.; Hertz, C.; Danial, N.N.; Moskowitz, M.A.; Korsmeyer, S.J. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc. Natl. Acad. Sci. USA？2005, 102, 12005–12010, doi:10.1073/pnas.0505294102. 16103352
